22 March 2021
EMA/CHMP/171652/2021
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Agenda for the meeting on 22-25 March 2021

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

22 March 2021, 09:00 – 19:30, virtual meeting/ room 1C

23 March 2021, 08:30 – 19:30, virtual meeting/ room 1C

24 March 2021, 08:30 – 19:30, virtual meeting/ room 1C

25 March 2021, 08:30 – 19:30, virtual meeting/ room 1C

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction 8

1.1. Welcome and declarations of interest of members, alternates and experts 8

1.2. Adoption of agenda 8

1.3. Adoption of the minutes 8

2. Oral Explanations 8

2.1. Pre-authorisation procedure oral explanations 8

2.1.1. satralizumab - Orphan - EMEA/H/C/004788 8

2.1.2. evinacumab - EMEA/H/C/005449 8

2.1.3. pitolisant - EMEA/H/C/005117 9

2.1.4. trastuzumab - EMEA/H/C/005066 9

2.1.5. trastuzumab - EMEA/H/C/005880 9

2.2. Re-examination procedure oral explanations 9

2.3. Post-authorisation procedure oral explanations 9

2.4. Referral procedure oral explanations 9

3. Initial applications 9

3.1. Initial applications; Opinions 9

3.1.1. duvelisib - Orphan - EMEA/H/C/005381 9

3.1.2. estetrol / drospirenone - EMEA/H/C/005336 10

3.1.3. hydrocortisone - Orphan - EMEA/H/C/005105 10

3.1.4. estetrol / drospirenone - EMEA/H/C/005382 10

3.1.5. ponesimod - EMEA/H/C/005163 10

3.1.6. COVID-19 Vaccine Janssen - COVID-19 vaccine (Ad26.COV2-S [recombinant]) - EMEA/H/C/005737 11

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) 11

3.2.1. eflornithine / sulindac - Orphan - EMEA/H/C/005043 11

3.2.2. setmelanotide - Orphan - EMEA/H/C/005089 11

3.2.3. insulin human (rDNA) - EMEA/H/C/005331 11

3.2.4. relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267 11

3.2.5. sildenafil - EMEA/H/C/005439 12

3.2.6. vericiguat - EMEA/H/C/005319 12

3.2.7. obeticholic acid - EMEA/H/C/005249 12

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) 12

3.3.1. fingolimod - EMEA/H/C/005661 12

3.3.2. finerenone - EMEA/H/C/005200 12

3.3.3. maralixibat - Orphan - EMEA/H/C/005551 12
3.3.4. metformin hydrochloride / sitagliptin hydrochloride monohydrate - EMEA/H/C/005678 13
3.3.5. arimoclomol - Orphan - EMEA/H/C/005203 13
3.3.6. adrenaline - EMEA/H/C/005584 13
3.3.7. lasmiditan - EMEA/H/C/005332 13
3.3.8. sitagliptin fumarate - EMEA/H/C/005741 13
3.3.9. tepotinib - EMEA/H/C/005524 13
3.3.10. teriparatide - EMEA/H/C/005543 14
3.4. Update on on-going initial applications for Centralised procedure 14
3.4.1. istradefylline - EMEA/H/C/005308 14
3.4.2. lonafarnib - Orphan - EMEA/H/C/005271 14
3.4.3. pegfilgrastim - EMEA/H/C/004780 14
3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 14
3.6. Initial applications in the decision-making phase 15
3.7. Withdrawals of initial marketing authorisation application 15

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 15

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion 15
4.1.1. Buvidal - buprenorphine - EMEA/H/C/004651/X/0008/G 15
4.1.2. Diacomit - stiripentol - EMEA/H/C/000664/X/0032 15
4.1.3. Skyrizi - risankizumab - EMEA/H/C/004759/X/0012 16
4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues 16
4.2.1. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0024/G 16
4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question 16
4.3.1. Noxafil - posaconazole - EMEA/H/C/000610/X/0063/G 16
4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 17
4.4.1. Bortezomib Accord - bortezomib - EMEA/H/C/003984/X/0023 17
4.4.2. Ferriprox - deferiprone - EMEA/H/C/000236/X/0145 17
4.4.3. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0030/G 17
4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 18

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 18

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information 18

5.1.1. Benlysta - belimumab - EMEA/H/C/002015/II/0080 18

5.1.2. Brilique - ticagrelor - EMEA/H/C/001241/II/0047/G 18

5.1.3. Firmagon - degarelix - EMEA/H/C/000986/II/0039/G 18

5.1.4. Galafold - migalastat - Orphan - EMEA/H/C/004059/II/0029 19

5.1.5. Kaftrio - ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA/H/C/005269/II/0001 19

5.1.6. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0089 19

5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0099 20

5.1.8. Libtayo - cemiplimab - EMEA/H/C/004844/II/0011 20

5.1.9. Libtayo - cemiplimab - EMEA/H/C/004844/II/0012 20

5.1.10. Noxafil - posaconazole - EMEA/H/C/000610/II/0062 21

5.1.11. Opdivo - nivolumab - EMEA/H/C/003985/II/0095 21

5.1.12. Opdivo - nivolumab - EMEA/H/C/003985/II/0096 21

5.1.13. Saxenda - liraglutide - EMEA/H/C/003780/II/0026 22

5.1.14. Spherox - spheroids of human autologous matrix-associated chondrocytes - ATMP - EMEA/H/C/002736/II/0020 22

5.1.15. Tagrisso - osimertinib - EMEA/H/C/004124/II/0039/G 22

5.1.16. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0033 22

5.1.17. Xtandi - enzalutamide - EMEA/H/C/002639/II/0047/G 23

5.1.18. Zeposia - ozanimod - EMEA/H/C/004835/II/0002/G 23

5.1.19. WS1840 Opdivo - nivolumab - EMEA/H/C/003985/WS1840/0089 Yervoy - ipilimumab - EMEA/H/C/002213/WS1840/0084 24

5.1.20. WS1881 Opdivo - nivolumab - EMEA/H/C/003985/WS1881/0091 Yervoy - ipilimumab - EMEA/H/C/002213/WS1881/0085 24

5.1.21. WS1937/G Eucreas - vildagliptin / metformin hydrochloride - EMEA/H/C/000807/WS1937/0080/G Icandra - vildagliptin / metformin hydrochloride - EMEA/H/C/001050/WS1937/0083/G Zomarist - vildagliptin / metformin hydrochloride - EMEA/H/C/001049/WS1937/0082/G 24

5.1.22. WS1938/G Galvus - vildagliptin - EMEA/H/C/000771/WS1938/0066/G Jalra - vildagliptin - EMEA/H/C/001048/WS1938/0068/G Xiliarx - vildagliptin - EMEA/H/C/001051/WS1938/0066/G 25

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 25

5.2.1. Brilique - ticagrelor - EMEA/H/C/001241/II/0049 25

5.2.2. Teysuno - tegafur / gimeracil / oteracil - EMEA/H/C/001242/II/0045 25

5.2.3. Venclyxto - venetoclax - EMEA/H/C/004106/II/0030 26

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 26

6. Ancillary medicinal substances in medical devices 26

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions 26

6.2. Update of Ancillary medicinal substances in medical devices 26

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 27

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)27

8. Pre-submission issues 27

8.1. Pre-submission issue 27

8.1.1. capmatinib – H0004845 27

8.2. Priority Medicines (PRIME) 27

8.2.1. List of applications received 27

8.2.2. Recommendation for PRIME eligibility 27

9. Post-authorisation issues 27

9.1. Post-authorisation issues 27

9.1.1. Ceplene - histamine dihydrochloride - EMEA/H/C/000796/S/0042 27

9.1.2. Nulojix - belatacept - EMEA/H/C/002098/II/0065/G 28

9.1.3. Remsima - infliximab - EMEA/H/C/002576/II/0095 28

9.1.4. Veklury - remdesivir - EMEA/H/C/005622/R/0015 28

9.1.5. Xeljanz - tofacitinib - EMEA/H/C/004214/II/0027 28

10. Referral procedures 29

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004 29

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 . 29

10.2.1. Regdanvimab – EMEA/H/A-5(3)/1505 29

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004 29

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC 29

10.4.1. Lidocain/ Prilocain IDETEC – lidocaine, prilocaine - EMEA/H/A-29(4)/1506 29

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC.... 30

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC 30

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC..... 30

10.8. Procedure under Article 107(2) of Directive 2001/83/EC 30

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 30

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006..... 30

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 30

11. Pharmacovigilance issue 30

11.1. Early Notification System 30

12. Inspections 31

12.1. GMP inspections 31

12.2. GCP inspections 31

12.3. Pharmacovigilance inspections 31

12.4. GLP inspections 31

13. Innovation Task Force 31

13.1. Minutes of Innovation Task Force 31

13.2. Innovation Task Force briefing meetings 31

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004 31

13.4. Nanomedicines activities 31

14. Organisational, regulatory and methodological matters 32

14.1. Mandate and organisation of the CHMP 32

14.2. Coordination with EMA Scientific Committees 32

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC) 32

14.2.2. Paediatric Committee (PDCO) 32

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 32

14.3.1. Biologics Working Party (BWP) 32

14.3.2. Biosimilar Medicinal Product Working Party (BMWP) 32

14.3.3. Biostatistics Working Party (BSWP) 33

14.3.4. Scientific Advice Working Party (SAWP) 33

14.3.5. Ad-hoc Influenza Working Group 33

14.3.6. Scientific Advisory Group (SAG) – preparation of launch of public call for expression of interests for renewal of mandate of all therapeutic SAGs 33

14.4. Cooperation within the EU regulatory network 33

14.5. Cooperation with International Regulators 33

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee 34

14.7. CHMP work plan 34

14.8. Planning and reporting 34

14.8.1. Update of the Business Pipeline report for the human scientific committees 34

14.9. Others 34

15. Any other business 34

15.1. AOB topic 34

15.1.1. Update on COVID-19 34

15.1.2. COVID-19 vaccine (NVX-CoV2373) – EMEA/H/C/005808 34

15.1.3. COVID-19 mRNA vaccine - EMEA/H/C/005845 34

15.1.4. COVID-19 vaccine - EMEA/H/C/005861 COVID-19 vaccine - EMEA/H/C/005875 35

16. Explanatory notes 35

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 22-25 March 2021. See March 2021 CHMP minutes (to be published post April 2021 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 22-25 March 2021

1.3. Adoption of the minutes

CHMP minutes for 22-25 February 2021.

Minutes from PRocedural and Organisational Matters (PROM) meeting (previously called ORGAM meeting) held on 15 February 2021.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. satralizumab - Orphan - EMEA/H/C/004788

Roche Registration GmbH; treatment of adult and adolescent patients from 12 years of age with neuromyelitis optica spectrum disorders (NMOSD)

Scope: Oral explanation

Action: Oral explanation to be held on Tuesday 23 March 2021 at 11:00

List of Outstanding Issues adopted on 28.05.2020. List of Questions adopted on 10.12.2019.

2.1.2. evinacumab - EMEA/H/C/005449

Accelerated assessment

treatment of homozygous familial hypercholesterolemia (HoFH)

Scope: Possible oral explanation

Action: Possible oral explanation to be held on Tuesday 23 March 2021 at 14:00

List of Questions adopted on 08.12.2020.

2.1.3. pitolisant - EMEA/H/C/005117

Treatment of Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnoea (OSA)

Scope: Possible oral explanation

Action: Possible oral explanation to be held on Wednesday 24 March 2021 at 09:00

List of Outstanding Issues adopted on 10.12.2020. List of Questions adopted on 25.06.2020.

2.1.4. trastuzumab - EMEA/H/C/005066

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Possible oral explanation

Action: Possible oral explanation to be held on Tuesday 23 March 2021 at 16:00

List of Outstanding Issues adopted on 10.12.2020. List of Questions adopted on 19.09.2019.

2.1.5. trastuzumab - EMEA/H/C/005880

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Possible oral explanation

Action: Possible oral explanation to be held on Tuesday 23 March 2021 at 16:00

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. duvelisib - Orphan - EMEA/H/C/005381

Verastem Europe GmbH; Treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) and relapsed or

refractory follicular lymphoma (FL)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 10.12.2020, 17.09.2020. List of Questions adopted on 30.04.2020.

3.1.2. estetrol / drospirenone - EMEA/H/C/005336

oral contraceptive

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 28.01.2021, 12.11.2020. List of Questions adopted on 25.06.2020.

3.1.3. hydrocortisone - Orphan - EMEA/H/C/005105

Diurnal Europe BV; replacement therapy for congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 28.01.2021. List of Questions adopted on 23.07.2020.

3.1.4. estetrol / drospirenone - EMEA/H/C/005382

oral contraception

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 28.01.2021, 12.11.2020. List of Questions adopted on 25.06.2020.

3.1.5. ponesimod - EMEA/H/C/005163

treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 28.01.2021. List of Questions adopted on 23.07.2020.

3.1.6. COVID-19 Vaccine Janssen - COVID-19 vaccine (Ad26.COV2-S [recombinant]) - EMEA/H/C/005737

Janssen-Cilag International N.V.; prevention of coronavirus disease-2019 (COVID-19)

Scope: Opinion was adopted at an extraordinary meeting held remotely on 11 March 2021

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. eflornithine / sulindac - Orphan - EMEA/H/C/005043

Cancer Prevention Pharma (Ireland) Limited; treatment of adults patients with familial adenomatous polyposis (FAP)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 15.10.2020.

3.2.2. setmelanotide - Orphan - EMEA/H/C/005089

TMC Pharma (EU) Limited; Treatment of obesity and the control of hunger associated with deficiencies in the leptin-melanocortin pathway

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 13.10.2020.

3.2.3. insulin human (rDNA) - EMEA/H/C/005331

treatment of patients with diabetes mellitus who require intravenous insulin

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.07.2020.

3.2.4. relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267

treatment of uterine fibroids

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 28.01.2021. List of Questions adopted on 23.07.2020.

3.2.5. sildenafil - EMEA/H/C/005439

treatment of erectile dysfunction

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 10.12.2020. List of Questions adopted on 25.06.2020.

3.2.6. vericiguat - EMEA/H/C/005319

treatment of symptomatic chronic heart failure

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 15.10.2020.

3.2.7. obeticholic acid - EMEA/H/C/005249

improvement of liver fibrosis and resolution of steatohepatitis in adult patients with significant liver fibrosis due to nonalcoholic steatohepatitis (NASH)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 28.05.2020.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. fingolimod - EMEA/H/C/005661

treatment of multiple sclerosis

Action: For adoption

3.3.2. finerenone - EMEA/H/C/005200

delay progression of kidney disease, reduce the risk of cardiovascular mortality and morbidity

Scope: List of questions

Action: For adoption

3.3.3. maralixibat - Orphan - EMEA/H/C/005551

FGK Representative Service GmbH; Treatment of Progressive Familial Intrahepatic Cholestasis Type 2

Scope: List of questions

Action: For adoption

3.3.4. metformin hydrochloride / sitagliptin hydrochloride monohydrate - EMEA/H/C/005678

treatment of type 2 diabetes mellitus

Scope: List of questions

Action: For adoption

3.3.5. arimoclomol - Orphan - EMEA/H/C/005203

Orphazyme A/S; treatment of Niemann-Pick disease type C (NPC)

Scope: List of questions

Action: For adoption

3.3.6. adrenaline - EMEA/H/C/005584

For the emergency treatment of allergic reactions, including anaphylaxis

Scope: List of questions

Action: For adoption

3.3.7. lasmiditan - EMEA/H/C/005332

acute treatment of migraine with or without aura in adults

Scope: List of questions

Action: For adoption

3.3.8. sitagliptin fumarate - EMEA/H/C/005741

treatment of type 2 diabetes mellitus

Scope: List of questions

Action: For adoption

3.3.9. tepotinib - EMEA/H/C/005524

treatment of adult patients with advanced non-small cell lung cancer

Scope: List of questions

Action: For adoption

3.3.10. teriparatide - EMEA/H/C/005543

treatment of osteoporosis

Scope: List of questions

Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. istradefylline - EMEA/H/C/005308

indicated as an adjunctive treatment to levodopa-based regimens in patients with Parkinson's disease

Scope: Letter from the applicant dated 18 March 2021 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in February 2021.

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 30.04.2020.

3.4.2. lonafarnib - Orphan - EMEA/H/C/005271

EigerBio Europe Limited; treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies

Scope: Letter from the applicant dated 15 March 2021 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in February 2021.

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 23.07.2020.

3.4.3. pegfilgrastim - EMEA/H/C/004780

treatment of neutropenia

Scope: Letter from the applicant dated 03 March 2021 requesting an extension of clock-stop to respond to the list of questions adopted in September 2020.

Action: For adoption

List of questions adopted on 17.09.2020

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

No items

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Buvidal - buprenorphine - EMEA/H/C/004651/X/0008/G

Camurus AB

Rapporteur: Peter Kiely, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Line extension to add a new strength of 160 mg for prolonged-release solution for injection pharmaceutical form.
In addition the MAH took the opportunity to align the PI to the latest QRD template and to implement new text regarding the content of ethanol in accordance with the EMA document "Information for the package leaflet regarding ethanol used as an excipient in medicinal products for human use" (EMA/CHMP/43486/2018) in the Package Leaflet.
Variations included:
A.4
A.5.b."

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 15.10.2020.

4.1.2. Diacomit - stiripentol - EMEA/H/C/000664/X/0032

BIOCODEX

Rapporteur: Alar Irs, PRAC Rapporteur: Maia Uusküla

Scope: "Extension application to add a new strength of 100 mg capsules. The RMP (version 2.0) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 12.11.2020. List of Questions adopted on 25.06.2020.

4.1.3. Skyrizi - risankizumab - EMEA/H/C/004759/X/0012

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Peter Kiely, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to add a new strength of 150 mg for solution for injection in a pre-filled syringe and pre-filled pen."

Action: For adoption

List of Questions adopted on 10.12.2020.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0024/G

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to introduce a new pharmaceutical form (oral solution, 1 mg/ml) grouped with a type II variation (C.I.6.a) to add a new indication (treatment of active polyarticular course juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older). The RMP (version 12.1) is updated in accordance. Additionally, the marketing authorisation holder took the opportunity to align the PI with the latest QRD template."

Action: For adoption

List of Questions adopted on 15.10.2020.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Noxafil - posaconazole - EMEA/H/C/000610/X/0063/G

Merck Sharp & Dohme B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli

Scope: "Extension application to introduce a new pharmaceutical form (gastro-resistant powder and solvent for oral suspension), grouped with a type II variation (C.I.6.a) to extend the approved indications for Noxafil to the paediatric population.
As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC, as well as the package leaflet, are updated. The RMP (version 17.1) is updated in accordance."

Action: For adoption

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.4.1. Bortezomib Accord - bortezomib - EMEA/H/C/003984/X/0023

Accord Healthcare S.L.U.

Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (2.5 mg/ml solution for injection)."

Letter from the applicant dated 04 March 2021 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in February 2021.

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 17.09.2020.

4.4.2. Ferriprox - deferiprone - EMEA/H/C/000236/X/0145

Chiesi Farmaceutici S.p.A.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension application to introduce a new pharmaceutical form (gastro-resistant tablets). The RMP (version 14.0) is updated in accordance."

Letter from the applicant dated 25 February 2021 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in February 2021.

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 17.09.2020.

4.4.3. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0030/G

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to add a new strength (22 mg prolonged-release tablet) grouped with a type II variation C.I.4: Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of Xeljanz 11 mg prolonged-release tablets SmPC in order to include the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent; as an alternative to the immediate release film-coated tablets, section 4.2 of Xeljanz film-coated tablets is also updated to include switching with the prolonged-release tablet in the treatment of UC. The Package Leaflet is updated accordingly. The RMP version 15.1 has also been submitted."

Letter from the applicant dated 10 March 2021 requesting an extension of clock-stop to respond to the list of questions adopted in February 2021.

Action: For adoption

List of Questions adopted on 25.02.2021.

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Benlysta - belimumab - EMEA/H/C/002015/II/0080

GlaxoSmithKline (Ireland) Limited

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of lupus nephritis for belimumab; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 38 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021, 15.10.2020.

5.1.2. Brilique - ticagrelor - EMEA/H/C/001241/II/0047/G

AstraZeneca AB

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Menno van der Elst

Scope: "C.1.4 Update of the SmPC sections 4.4 and 4.8 to include information on ticagrelor and traumatic hemorrhages, based on data from the THEMIS study and on the totality of data from the clinical development program and post-marketing use."

The MAH has requested a withdrawal of the C.I.6 variation from the grouping. The assessment will continue for the type II C.I.4.

Action: For adoption

5.1.3. Firmagon - degarelix - EMEA/H/C/000986/II/0039/G

Ferring Pharmaceuticals A/S

Rapporteur: Alexandre Moreau

Scope: "Extension of indications to include:
• Extension of indication to include treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. As a consequence, sections 4.1, 4.2, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.
• Extension of indication to include treatment as neo-adjuvant prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer. As a consequence, sections 4.1, 4.2, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance."

Action: For adoption

5.1.4. Galafold - migalastat - Orphan - EMEA/H/C/004059/II/0029

Amicus Therapeutics Europe Limited

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication for Galafold (migalastat) to include long-term treatment of adolescents 12 to < 16 years with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation. As a consequence, sections 4.1, 4.2, 4.8 and 5.2 of the SmPC and section 1 and 2 of the Package Leaflet are updated accordingly. A revised RMP version 4.0 has also been submitted."

Action: For adoption

5.1.5. Kaftrio - ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA/H/C/005269/II/0001

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication of Kaftrio to patients with CF aged 12 years and older who have at least one F508del mutation in the CFTR gene, regardless of the second allele (F/any). Efficacy data are summarised from study 104, which was conducted in subjects heterozygous for F508del and a gating (G) or residual function (RF) mutation (F/G and F/RF genotypes).
As a consequence update of SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 are requested. Package insert is updated accordingly. The RMP is updated version 1.1"

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

5.1.6. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0089

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication to extend the indication of Kalydeco (ivacaftor) tablets in combination regimen with Kaftrio (ivacaftor/tezacaftor/elexacaftor) tablets for the

treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene; as a consequence, sections 4.1, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0099

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 31.1 of the RMP has also been submitted."

Action: For adoption

5.1.8. Libtayo - cemiplimab - EMEA/H/C/004844/II/0011

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for LIBTAYO as monotherapy indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:
• locally advanced NSCLC and who are not candidates for surgical resection or definitive chemoradiation, or have progressed after treatment with definitive chemoradiation, or
• metastatic NSCLC.
The PL is revised accordingly. A revised RMP is submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

5.1.9. Libtayo - cemiplimab - EMEA/H/C/004844/II/0012

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include: Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor.

SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 have been revised. The PL has been updated accordingly. A revised RMP has been submitted."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

5.1.10. Noxafil - posaconazole - EMEA/H/C/000610/II/0062

Merck Sharp & Dohme B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli

Scope: "Extension of indication to include primary treatment of invasive aspergillosis in adults and adolescents from 13 years of age for Noxafil gastroresistant tablet and concentrate for solution for infusion as result of conclusion of study P069 (a Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.
Version 16.2 of the RMP has also been submitted."

Action: For adoption

5.1.11. Opdivo - nivolumab - EMEA/H/C/003985/II/0095

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include adjuvant treatment of adult patients with resected oesophageal, or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy for Opdivo (study CA209577); as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 22.0 of the RMP has also been submitted."

Action: For adoption

5.1.12. Opdivo - nivolumab - EMEA/H/C/003985/II/0096

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to use Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy, in first-line treatment of adult patients with advanced or metastatic gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma (Study CA209649); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 21.0 of the RMP has also been submitted."

Action: For adoption

5.1.13. Saxenda - liraglutide - EMEA/H/C/003780/II/0026

Novo Nordisk A/S

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment as an adjunct to a healthy nutrition and physical activity counselling for weight management in adolescent patients from the age of 12 years and above with body weight above 60 kg and obesity (BMI corresponding to ≥ 30 kg/m2 for adults), based on study NN8022-4180 that evaluated the efficacy of liraglutide 3.0 mg in adolescents aged 12 to less than 18 years with obesity. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are being updated and the Package Leaflet is updated in accordance. The application relates to paediatric studies submitted according to Article 46 of the paediatric regulation. The application included an updated RMP version 32.0."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021, 15.10.2020, 28.05.2020.

5.1.14. Spherox - spheroids of human autologous matrix-associated chondrocytes - ATMP - EMEA/H/C/002736/II/0020

CO.DON AG

Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder

Scope: "Extension of the indication for use in the paediatric population (15 to 18 years)."

Action: For adoption

5.1.15. Tagrisso - osimertinib - EMEA/H/C/004124/II/0039/G

AstraZeneca AB

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication of Tagrisso to include the adjuvant treatment after complete tumour resection in EGFR mutant non-small cell lung cancer (NSCLC) patients, based on the results from the pivotal Phase 3 randomised, placebo-controlled study ADAURA (D5164C00001); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 14.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

5.1.16. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0033

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1 for Tecentriq based on the results of the pivotal study GO29431 (IMpower110), comparing atezolizumab monotherapy to platinum-based chemotherapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. The RMP version 12.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021, 26.03.2020.

5.1.17. Xtandi - enzalutamide - EMEA/H/C/002639/II/0047/G

Astellas Pharma Europe B.V.

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia

Scope: "C.1.6: Extension of indication to include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) for Xtandi in combination with androgen deprivation therapy. As a consequence, sections 4.1, 4.7, 4.8, 5.1, 5.3 and 6.6 of the SmPC are updated. Furthermore, the MAH took the opportunity to make corrections to section 4.7. The Package Leaflet is updated in accordance. The RMP version 13.0 has also been submitted.
C.1.4: Update of section 5.1 of the SmPC based the 5-year Overall Survival (OS) results obtained from the PREVAIL study (MDV310003), a phase 3 study of enzalutamide in chemotherapy naïve patients with metastatic prostate cancer that progressed on ADT."

Action: For adoption

Request for Supplementary Information adopted on 28.05.2020, 17.10.2019.

5.1.18. Zeposia - ozanimod - EMEA/H/C/004835/II/0002/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Bruno Sepodes, Co-Rapporteur: Martina Weise, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "C.I.6 (Extension of indication)
Extension of indication to include the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent for Zeposia; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.2 and 5.1 of the SmPC and Annex IID are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes throughout the product information.
C.I.4 Update of sections 4.4 and 4.5 of the SmPC in order to update the current SmPC description about PK interaction with BCRP inhibitors based on the study report from a drug interaction study with cyclosporine l(RPC-1063-CP-001)."

Action: For adoption

5.1.19. WS1840
Opdivo - nivolumab - EMEA/H/C/003985/WS1840/0089
Yervoy - ipilimumab - EMEA/H/C/002213/WS1840/0084

Bristol-Myers Squibb Pharma EEIG

Lead Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC) for combination treatment with Opdivo and Yervoy; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 18.0 for Opdivo and version 29.0 for Yervoy of the RMP have also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 12.11.2020.

5.1.20. WS1881
Opdivo - nivolumab - EMEA/H/C/003985/WS1881/0091
Yervoy - ipilimumab - EMEA/H/C/002213/WS1881/0085

Bristol-Myers Squibb Pharma EEIG

Lead Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) for Opdivo in combination with Yervoy; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 20.0 for Opdivo and version 30.0 for Yervoy of the RMP have also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

5.1.21. WS1937/G
Eucreas - vildagliptin / metformin hydrochloride - EMEA/H/C/000807/WS1937/0080/G
Icandra - vildagliptin / metformin hydrochloride - EMEA/H/C/001050/WS1937/0083/G
Zomarist - vildagliptin / metformin hydrochloride - EMEA/H/C/001049/WS1937/0082/G

Novartis Europharm Limited

Lead Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin

Scope: "Modification of approved therapeutic indication to simplify wording. Update of SmPC section 5.1 to add VERIFY study data (new study). Existing warning on drugs that may affect renal function or metformin disposition was expanded to include drugs that inhibit renal transporter (OCT2/MATE inhibitors) and corresponding update in drug interaction (sections 4.4 and 4.5). PI update to QRD v10.1."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021.

5.1.22. WS1938/G
Galvus - vildagliptin - EMEA/H/C/000771/WS1938/0066/G
Jalra - vildagliptin - EMEA/H/C/001048/WS1938/0068/G
Xiliarx - vildagliptin - EMEA/H/C/001051/WS1938/0066/G

Novartis Europharm Limited

Lead Rapporteur: Kristina Dunder

Scope: "Modification of approved therapeutic indication to simplify wording. Update of SmPC section 5.1 to add VERIFY study data (new study)."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Brilique - ticagrelor - EMEA/H/C/001241/II/0049

AstraZeneca AB

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include, in co-administration with acetylsalicylic acid (ASA), the prevention of stroke in adult patients with acute ischaemic stroke or transient ischaemic attack (TIA), based on the final results of study D5134C00003 (THALES), a phase III, international, multicentre, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of ticagrelor and ASA compared with ASA in the prevention of stroke and death in patients with acute ischaemic stroke or transient ischaemic attack; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13 of the RMP has also been submitted."

Letter from the applicant dated 02 March 2021 requesting an extension of clock-stop to respond to the request for supplementary information adopted in November 2020; the clock stop extension was adopted via written procedure on 10 March 2021.

Action: For information

Request for Supplementary Information adopted on 28.01.2021, 17.09.2020.

5.2.2. Teysuno - tegafur / gimeracil / oteracil - EMEA/H/C/001242/II/0045

Nordic Group B.V.

Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of metastatic colorectal cancer in adult patients where it is not possible to initiate or continue treatment with another

fluoropyrimidine. As a consequence, sections 4.1, 4.2, 4.3, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10 of the RMP has also been submitted."

Letter from the applicant dated 12 March 2021 requesting an extension of clock-stop to respond to the request for supplementary information adopted in January 2021.

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021

5.2.3. Venclyxto - venetoclax - EMEA/H/C/004106/II/0030

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Filip Josephson, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Eva Jirsová

Scope: "Extension of indication for Venclyxto (venetoclax) in combination with Hypomethylating Agents (HMAs) or Low Dose Cytarabine (LDAC) for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. As a consequence, sections 4.2, 4.3, 4.4, 4.5, 4.7, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and RMP version 6.1 are also updated accordingly.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Draft list of experts for SAG Oncology meeting

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021, 15.10.2020.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. capmatinib – H0004845

is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Ceplene - histamine dihydrochloride - EMEA/H/C/000796/S/0042

Noventia Pharma S.r.l.

Rapporteur: Jayne Crowe, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Rhea

Fitzgerald

Scope: Annual reassessment

Action: For adoption

9.1.2. Nulojix - belatacept - EMEA/H/C/002098/II/0065/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Filip Josephson

Scope: "B.I.a.2.c
B.I.b.1.c
B.I.b.2.b."

Action: For adoption

Request for Supplementary Information adopted on 12.11.2020, 12.03.2020.

9.1.3. Remsima - infliximab - EMEA/H/C/002576/II/0095

Celltrion Healthcare Hungary Kft.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Addition of a new posology for the rheumatoid arthritis indication that does not include IV induction doses."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

9.1.4. Veklury - remdesivir - EMEA/H/C/005622/R/0015

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Eva Jirsová

Scope: Renewal of conditional marketing authorisation

Action: For discussion

9.1.5. Xeljanz - tofacitinib - EMEA/H/C/004214/II/0027

Pfizer Europe MA EEIG,

Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Update of sections 4.1, 4.2, 4.4 , 4.8, 5.1 and 5.2 of Xeljanz 11 mg prolonged-release tablets SmPC in order to include the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug therapy; as an alternative to the immediate release film-coated tablets; section 4.2 of Xeljanz film-coated tablets is also updated to include switching with the prolonged-release tablet in the treatment of PsA. The Package Leaflet is updated accordingly. The RMP version 13.1 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Regdanvimab – EMEA/H/A-5(3)/1505

Celltrion Healthcare

Referral Rapporteur: Filip Josephson, Referral Co-Rapporteur: Jan Mueller-Berghaus

Scope: Opinion

Rapporteurs were appointed via written procedure on 01.03.2021.

Action: For adoption

The Committee for Medicinal Products for Human Use (CHMP) was asked by EMA to give a scientific opinion on potential use of regdanvimab for the treatment of COVID-19 patients that do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19.

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Lidocain/ Prilocain IDETEC – lidocaine, prilocaine - EMEA/H/A-29(4)/1506

International Drug Development France

Scope: Start of procedure, list of questions, timetable, appointment of Rapporteurs

Action: For adoption

Summary: Decentralised Procedure number: DK/H/3106/001/DC, notification by the Danish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting MS is of the opinion that therapeutic equivalence has not been demonstrated between the test and the reference product.

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

March 2021 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

No items

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 08-11 March 2021

Action: For information

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for March 2021

Action: For adoption

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at March 2021 PDCO

Action: For information

Report from the PDCO meeting held on 23-26 March 2021

Action: For information

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP March 2021 meeting to CHMP for adoption:

- 12 reports on products in scientific advice and protocol assistance
- 5 reports on products in pre-authorisation procedures
- 1 reports on products in plasma master file

Action: For adoption

14.3.2. Biosimilar Medicinal Product Working Party (BMWP)

Chair: Elena Wolff-Holz

Election of a BMWP Vice-Chair. The mandate of the BMWP Vice-Chair Niklas Ekman expired

in September 2020.

Nomination(s) received

Action: For election

14.3.3. Biostatistics Working Party (BSWP)

Chair: Kit Roes

Election of a BSWP Vice-Chair. The mandate of the BSWP Vice-Chair Jörg Zinserling expired in January 2021.

Nomination(s) received

Action: For election

14.3.4. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 08-11 March 2021. Table of conclusions

Action: For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.5. Ad-hoc Influenza Working Group

Scope: EU Strain selection for the Influenza Vaccines for the Season 2021/2022: Report from the Ad Hoc Influenza working group to the BWP

Action: For adoption

Scope: EU Recommendation for the Seasonal Influenza Vaccine Composition for the Season 2021/2022

Action: For adoption

14.3.6. Scientific Advisory Group (SAG) – preparation of launch of public call for expression of interests for renewal of mandate of all therapeutic SAGs

Action: For discussion

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

14.8.1. Update of the Business Pipeline report for the human scientific committees

2021 initial marketing authorisation application submissions with eligibility request to central procedure

Action: For information

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

15.1.2. COVID-19 vaccine (NVX-CoV2373) – EMEA/H/C/005808

prevention of COVID-19

Scope: Rolling review timetable adopted via written procedure on 8 March 2021

Action: For information

15.1.3. COVID-19 mRNA vaccine - EMEA/H/C/005845

prevention of COVID-19

Scope: Rolling review timetable adopted via written procedure on 01 March 2021

Action: For information

15.1.4. COVID-19 vaccine - EMEA/H/C/005861
COVID-19 vaccine - EMEA/H/C/005875

prevention of COVID-19

Scope: Rolling review list of questions together with the rolling review timetable adopted via written procedure on 19 March 2021.

Action: For information

16. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under

section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

22 March 2021
EMA/CHMP/171226/2021

Annex to 22-25 March 2021 CHMP Agenda

Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES 3
A.1. ELIGIBILITY REQUESTS 3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications 3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION 3

B. POST-AUTHORISATION PROCEDURES OUTCOMES 3
B.1. Annual re-assessment outcomes 3
B.1.1. Annual reassessment for products authorised under exceptional circumstances 3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES 4
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal 4
B.2.2. Renewals of Marketing Authorisations for unlimited validity 4
B.2.3. Renewals of Conditional Marketing Authorisations 4
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES 5
B.4. EPARs / WPARs 8
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES 9
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects 9
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects 14
B.5.3. CHMP-PRAC assessed procedures 25
B.5.4. PRAC assessed procedures 33
B.5.5. CHMP-CAT assessed procedures 38
B.5.6. CHMP-PRAC-CAT assessed procedures 39
B.5.7. PRAC assessed ATMP procedures 39
B.5.8. Unclassified procedures and worksharing procedures of type I variations 39
B.5.9. Information on withdrawn type II variation / WS procedure 43
B.5.10. Information on type II variation / WS procedure with revised timetable 43
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION 43
B.6.1. Start of procedure for New Applications: timetables for information 43
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information 43
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information 43

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

B.6.4. Annual Re-assessments: timetables for adoption 44
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed 44
B.6.6. VARIATIONS – START OF THE PROCEDURE 44
B.6.7. Type II Variations scope of the Variations: Extension of indication 45
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects 45
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects 46
B.6.10. CHMP-PRAC assessed procedures 52
B.6.11. PRAC assessed procedures 54
B.6.12. CHMP-CAT assessed procedures 57
B.6.13. CHMP-PRAC-CAT assessed procedures 57
B.6.14. PRAC assessed ATMP procedures 57
B.6.15. Unclassified procedures and worksharing procedures of type I variations 57
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY 59
B.7.1. Yearly Line listing for Type I and II variations 59
B.7.2. Monthly Line listing for Type I variations 59
B.7.3. Opinion on Marketing Authorisation transfer (MMD only) 59
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only) 59
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only) 59
B.7.6. Notifications of Type I Variations (MMD only) 59

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) 59

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) 59

E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES 59
E.1. PMF Certification Dossiers: 59
E.1.1. Annual Update 59
E.1.2. Variations: 59
E.1.3. Initial PMF Certification: 59
E.2. Time Tables – starting & ongoing procedures: For information 59

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver 60
F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended 60
F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health 60

G. ANNEX G 60
G.1. Final Scientific Advice (Reports and Scientific Advice letters): 60
G.2. PRIME 60
G.2.1. List of procedures concluding at 22-25 March 2021 CHMP plenary: 60
G.2.2. List of procedures starting in March 2021 for April 2021 CHMP adoption of outcomes 60

H. ANNEX H - Product Shared Mailboxes – e-mail address..... 60

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for March 2021: **For adoption**

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for March 2021: **For adoption**

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Ceplene - histamine dihydrochloride - EMEA/H/C/000796/S/0042 Noventia Pharma S.r.l., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald	See 9.1
Obizur - susoctocog alfa - EMEA/H/C/002792/S/0039 Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski	
Raxone - idebenone - EMEA/H/C/003834/S/0023, Orphan Santhera Pharmaceuticals (Deutschland) GmbH, Rapporteur: John Joseph Borg, PRAC Rapporteur: Amelia Cupelli Request for Supplementary Information adopted on 28.01.2021.	
Vyndaqel - tafamidis - EMEA/H/C/002294/S/0065, Orphan Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Tiphaine Vaillant	

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

Cinqaero - reslizumab -
EMEA/H/C/003912/R/0038
Teva B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Brigitte Keller-Stanislawski
Request for Supplementary Information adopted on 25.02.2021.

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Kisplyx - lenvatinib -
EMEA/H/C/004224/R/0043
Eisai GmbH, Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: David Olsen

Qtern - saxagliptin / dapagliflozin -
EMEA/H/C/004057/R/0030
AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Ilaria Baldelli
Request for Supplementary Information adopted on 28.01.2021.

Sialanar - glycopyrronium -
EMEA/H/C/003883/R/0018
Proveca Pharma Limited, Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Zane Neikena

Tenofovir disoproxil Zentiva - tenofovir disoproxil - EMEA/H/C/004120/R/0023
Zentiva k.s., Generic, Generic of Viread, Rapporteur: John Joseph Borg, PRAC Rapporteur: Adrien Inoubli

B.2.3. Renewals of Conditional Marketing Authorisations

LIBTAYO - cemiplimab -
EMEA/H/C/004844/R/0017
Regeneron Ireland Designated Activity Company (DAC), Rapporteur: Sinan B. Sarac, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Rozlytrek - entrectinib -
EMEA/H/C/004936/R/0002
Roche Registration GmbH, Rapporteur:

Armando Genazzani, PRAC Rapporteur: Menno van der Elst	
Veklury - remdesivir - EMEA/H/C/005622/R/0015 Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Eva Jirsová	See 9.1
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/R/0012, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, Co-Rapporteur: Egbert Flory, CHMP Coordinators: Johann Lodewijk Hillege and Jan Mueller-Berghaus, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 22.01.2021.	

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on 08-11 March 2021
PRAC:

Signal of major adverse cardiovascular events (MACE) and malignancies excluding non-melanoma skin cancer (NMSC) from a clinical trial

Xeljanz - tofacitinib
CHMP Rapporteur: Armando Genazzani
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: PRAC recommendation on a DHPC.
The DHPC and communication plan were adopted by CHMP via written procedure on 15.03.2021
Action: For information

Signal of anaphylactic reaction

COVID-19 Vaccine AstraZeneca (Other viral vaccines) - COVID-19 Vaccine (ChAdOx1-S [recombinant])
Rapporteur: Sol Ruiz, Co-Rapporteur: Johann Lodewijk Hillege
PRAC Rapporteur: Jean-Michel Dogné
Scope: PRAC recommendation on a variation / LEG submission
Action: For adoption

Signal of drug reaction with eosinophilia and systemic symptoms (DRESS)

Kineret, Ilaris - Anakinra, Canakinumab
Kineret: Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Fátima Ventura
Ilaris: Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Outi Mäki-Ikola
PRAC Rapporteur: Hans Christian Siersted
Scope: PRAC recommendation on a variation
Action: For adoption

Signal of extravasation and epidermal necrosis

Kadcyla - Trastuzumab emtansine
Rapporteur: Sinan B Sarac, Co-Rapporteur: Armando Genazzani
PRAC Rapporteur: Anette Kirstine Stark
Scope: PRAC recommendation on a variation
Action: For adoption

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its March 2021 meeting:

EMEA/H/C/PSUSA/00000459/202007
(buprenorphine (other formulations except for implant))
CAPS:
Buvidal (EMEA/H/C/004651) (buprenorphine), Camurus AB, Rapporteur: Peter Kiely
NAPS:
NAP - EU
PRAC Rapporteur: Tiphaine Vaillant, "31/07/2017 To: 30/07/2020"

EMEA/H/C/PSUSA/00002127/202008
(natalizumab)
CAPS:
Tysabri (EMEA/H/C/000603) (natalizumab), Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "06/08/2019 To: 06/08/2020"

EMEA/H/C/PSUSA/00010007/202007
(ribavirin (oral formulations))
CAPS:
Rebetol (EMEA/H/C/000246) (ribavirin), Merck Sharp & Dohme B.V., Rapporteur: Jean-Michel Race
NAPS:
NAPs - EU
PRAC Rapporteur: Adrien Inoubli, "24/07/2017 To: 24/07/2020"

EMEA/H/C/PSUSA/00010082/202008
(cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil)
CAPS:
Stribild (EMEA/H/C/002574) (elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil), Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ana Sofia Diniz Martins, "27/08/2019 To: 26/08/2020"

EMEA/H/C/PSUSA/00010438/202007
(sacubitril / valsartan)
CAPS:
Entresto (EMEA/H/C/004062) (sacubitril / valsartan), Novartis Europharm Limited, Rapporteur: Johann Lodewijk Hillege
Neparvis (EMEA/H/C/004343) (sacubitril / valsartan), Novartis Europharm Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Anette Kirstine Stark, "01/08/2019 To: 31/07/2020"

EMEA/H/C/PSUSA/00010544/202008
(palbociclib)
CAPS:
IBRANCE (EMEA/H/C/003853) (palbociclib), Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, PRAC Rapporteur: Anette Kirstine Stark, "03/08/2019 To: 02/08/2020"

EMEA/H/C/PSUSA/00010823/202008
(upadacitinib)
CAPS:
Rinvoq (EMEA/H/C/004760) (upadacitinib), AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "14/02/2020 To: 14/08/2020"

B.4. EPARs / WPARs

Abevmy - bevacizumab - EMEA/H/C/005327 Mylan IRE Healthcare Limited, Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer. First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer. First-line treatment of patients with advanced and/or metastatic renal cell cancer., Similar biological application (Article 10(4) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Abiraterone Accord - abiraterone acetate - EMEA/H/C/005408 Accord Healthcare S.L.U., treatment of metastatic prostate cancer, Generic, Generic of Zytiga, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Evrysdi - risdiplam - EMEA/H/C/005145, Orphan Roche Registration GmbH, treatment of spinal muscular atrophy (SMA), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
JEMPERLI - dostarlimab - EMEA/H/C/005204 GlaxoSmithKline (Ireland) Limited, treatment of mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Lextemy - bevacizumab - EMEA/H/C/005611 Mylan IRE Healthcare Limited, Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer. First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer. First line treatment of patients with advanced and/or metastatic renal cell cancer., Duplicate, Duplicate of Abevmy, Similar biological application (Article 10(4) of Directive No	For information only. Comments can be sent to the PL in case necessary.

2001/83/EC)	
Orladeyo - berotralstat - EMEA/H/C/005138, Orphan BioCryst Ireland Limited, prevention of hereditary angioedema (HAE), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

AYVAKYT - avapritinib - EMEA/H/C/005208/II/0002, Orphan Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa Opinion adopted on 04.03.2021. Request for Supplementary Information adopted on 14.01.2021.	Positive Opinion adopted by consensus on 04.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
AYVAKYT - avapritinib - EMEA/H/C/005208/II/0003/G, Orphan Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa Request for Supplementary Information adopted on 04.02.2021.	
Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMEA/H/C/002333/II/0100/G GSK Vaccines S.r.l, Rapporteur: Kristina Dunder Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0011/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 09.03.2021.	Positive Opinion adopted by consensus on 09.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0012 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 12.03.2021.	Positive Opinion adopted by consensus on 12.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COVID-19 Vaccine Moderna - COVID-19 mRNA vaccine (nucleoside-modified) -	

EMEA/H/C/005791/II/0007/G
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus

Cystagon - mercaptamine bitartrate - EMEA/H/C/000125/II/0062
Recordati Rare Diseases, Rapporteur: Maria Concepcion Prieto Yerro
Request for Supplementary Information adopted on 04.02.2021.

Darunavir Mylan - darunavir - EMEA/H/C/004068/II/0012
Mylan S.A.S, Generic, Generic of Prezista, Rapporteur: John Joseph Borg
Request for Supplementary Information adopted on 14.01.2021.

Elonva - corifollitropin alfa - EMEA/H/C/001106/II/0055
Merck Sharp & Dohme B.V., Rapporteur: Paula Boudewina van Hennik

Elonva - corifollitropin alfa - EMEA/H/C/001106/II/0056/G
Merck Sharp & Dohme B.V., Rapporteur: Paula Boudewina van Hennik

Elonva - corifollitropin alfa - EMEA/H/C/001106/II/0057
Merck Sharp & Dohme B.V., Rapporteur: Paula Boudewina van Hennik

Entyvio - vedolizumab - EMEA/H/C/002782/II/0058
Takeda Pharma A/S, Rapporteur: Armando Genazzani

Firmagon - degarelix - EMEA/H/C/000986/II/0038
Ferring Pharmaceuticals A/S, Rapporteur: Alexandre Moreau
Request for Supplementary Information adopted on 14.01.2021.

Forsteo - teriparatide - EMEA/H/C/000425/II/0056
Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau
Request for Supplementary Information adopted on 11.02.2021.

Herzuma - trastuzumab - EMEA/H/C/002575/II/0035/G
Celltrion Healthcare Hungary Kft., Rapporteur:

Jan Mueller-Berghaus Request for Supplementary Information adopted on 28.01.2021.	
Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0122 CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 14.01.2021.	
Intrarosa - prasterone - EMEA/H/C/004138/II/0015 Endoceutics S.A., Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
Kalydeco - ivacaftor - EMEA/H/C/002494/II/0093, Orphan Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
MVASI - bevacizumab - EMEA/H/C/004728/II/0017 Amgen Technology (Ireland) Unlimited Company, Duplicate, Duplicate of KYOMARC, Rapporteur: Bjorg Bolstad Opinion adopted on 04.03.2021. Request for Supplementary Information adopted on 14.01.2021.	Positive Opinion adopted by consensus on 04.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Nulojix - belatacept - EMEA/H/C/002098/II/0065/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson Request for Supplementary Information adopted on 12.11.2020, 12.03.2020.	See 9.1
Orencia - abatacept - EMEA/H/C/000701/II/0145/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Outi Mäki-Ikola	
Quofenix - delafloxacin - EMEA/H/C/004860/II/0007/G A. Menarini Industrie Farmaceutiche Riunite s.r.l., Rapporteur: Janet Koenig Opinion adopted on 18.03.2021. Request for Supplementary Information adopted on 14.01.2021.	Positive Opinion adopted by consensus on 18.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
ReFacto AF - moroctocog alfa -	Request for supplementary information adopted

EMEA/H/C/000232/II/0158/G Pfizer Europe MA EEIG, Rapporteur: Kirstine Moll Harboe Request for Supplementary Information adopted on 11.03.2021.	with a specific timetable.
Rixubis - nonacog gamma - EMEA/H/C/003771/II/0035/G Baxalta Innovations GmbH, Rapporteur: Andrea Laslop Opinion adopted on 11.03.2021. Request for Supplementary Information adopted on 14.01.2021, 08.10.2020.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Taltz - ixekizumab - EMEA/H/C/003943/II/0041 Eli Lilly Nederland B.V., Rapporteur: Kristina Dunder Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Toujeo - insulin glargine - EMEA/H/C/000309/II/0117/G Sanofi-Aventis Deutschland GmbH, Duplicate, Duplicate of Lantus, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 14.01.2021.	
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and Haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0073 MCM Vaccine B.V., Rapporteur: Christophe Focke Opinion adopted on 18.03.2021.	Positive Opinion adopted by consensus on 18.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and Haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0074 MCM Vaccine B.V., Rapporteur: Christophe Focke Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Verkazia - ciclosporin - EMEA/H/C/004411/II/0013/G, Orphan Santen Oy, Duplicate, Duplicate of IKERVIS, Rapporteur: Peter Kiely	
Vyxeos liposomal - daunorubicin / cytarabine - EMEA/H/C/004282/II/0019, Orphan	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

Jazz Pharmaceuticals Ireland Limited, Rapporteur: Johanna Lähteenvuo Opinion adopted on 11.03.2021.	recommendation.
Yellox - bromfenac - EMEA/H/C/001198/II/0025 Bausch Health Ireland Limited, Rapporteur: Kirstine Moll Harboe Request for Supplementary Information adopted on 11.03.2021, 03.09.2020.	Request for supplementary information adopted with a specific timetable.
WS1974 **Ratiograstim-EMEA/H/C/000825/ WS1974/0070** **Tevagrastim-EMEA/H/C/000827/ WS1974/0078** TEVA GmbH, Duplicate, Duplicate of Biograstim (SRD), Lead Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 04.02.2021.	
WS1981 **Abseamed-EMEA/H/C/000727/WS1981/ 0093** **Binocrit-EMEA/H/C/000725/WS1981/ 0092** **Epoetin alfa Hexal-EMEA/H/C/000726/ WS1981/0092** Sandoz GmbH, Lead Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
WS1997 **Actrapid-EMEA/H/C/000424/WS1997/ 0080** **Fiasp-EMEA/H/C/004046/WS1997/0026** **Levemir-EMEA/H/C/000528/WS1997/ 0102** **NovoRapid-EMEA/H/C/000258/WS1997/ 0139** **Ryzodeg-EMEA/H/C/002499/WS1997/ 0043** **Saxenda-EMEA/H/C/003780/WS1997/ 0028** **Tresiba-EMEA/H/C/002498/WS1997/0050** **Victoza-EMEA/H/C/001026/WS1997/0058** **Xultophy-EMEA/H/C/002647/WS1997/ 0040** Novo Nordisk A/S, Lead Rapporteur: Kirstine Moll Harboe Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

WS2001 **Hexacima-EMEA/H/C/002702/WS2001/0113** **Hexyon-EMEA/H/C/002796/WS2001/0117** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2016/G **Blitzima-EMEA/H/C/004723/WS2016/0039/G** **Ritemvia-EMEA/H/C/004725/WS2016/0039/G** **Truxima-EMEA/H/C/004112/WS2016/0042/G** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz	
WS2020 **Blitzima-EMEA/H/C/004723/WS2020/0038** **Ritemvia-EMEA/H/C/004725/WS2020/0038** **Truxima-EMEA/H/C/004112/WS2020/0041** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz	

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0085, Orphan Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, "Update of the SmPC section 5.1 with the 5 year long-term follow up and final OS results for the C25007 study in HL. Editorial updates have been also implemented in the PI." Request for Supplementary Information adopted on 28.01.2021.	
Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0086, Orphan Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, "Update of the SmPC section 5.1 following the submission of the CSR addendum which includes long-term follow up or final OS results for the AETHERA study "A phase 3, randomised, double-blind, placebo-controlled, multicentre, clinical trial in patients with Hodgkin Lymphoma (HL) at risk of relapse	

or progression following ASCT””	
Akynzeo - fosnetupitant / netupitant / palonosetron - EMEA/H/C/003728/II/0034 Helsinn Birex Pharmaceuticals Limited, Rapporteur: Peter Kiely, “submission of the results of the in vitro study assessing the ability of fosnetupitant to inhibit all UGTs of interest: UGT1A1, 1A3, 1A4, 1A6, 1A9, and 2B7 following a recommendation from the CHMP.”	
Bosulif - bosutinib - EMEA/H/C/002373/II/0048 Pfizer Europe MA EEIG, Rapporteur: Janet Koenig, “C.I.4 Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update safety and efficacy information based on final results from study B18711053 (a recommendation of EMEA/H/C002373/II/25/G). This is an interventional safety and efficacy study covering submission of the long-term experience results secondary endpoints (duration of MMR and CCyR, EFS and OS). The Safety Data pool is also updated with results of interventional studies, B18711048 (final CSR submitted in variation II/41) and ongoing studies B18711039 and B18711040 (listed as category 3 studies in the RMP); the Package Leaflet is updated accordingly. PSUR Annex IV associated to procedure EMEA/H/C/PSUSA/00010073/202003 (commission decision dated 14 December 2020) has been proposed for removal” Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
Deltyba - delamanid - EMEA/H/C/002552/II/0048, Orphan Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, “Update of section 5.1 of the SmPC in order to include information on epidemiological cut-off and clinical breakpoint. In addition, the MAH took the opportunity to propose an editorial update in Annex II and Spanish translation of SmPC section 4.8.” Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
Eylea - aflibercept - EMEA/H/C/002392/II/0067 Bayer AG, Rapporteur: Alexandre Moreau, “C.I.4 - change in the expression of qualitative	

and quantitative composition." Request for Supplementary Information adopted on 14.01.2021.	
Fabrazyme - agalsidase beta - EMEA/H/C/000370/II/0119 Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC following the submission of the final report following CHMP conclusions on the related post-authorisation measure (MEA 57.12) from the Fabry registry, a global, observational and voluntary program designed to collect uniform and meaningful clinical data related to the onset, progression, and treated course of patients with Fabry disease. This is a long-term effectiveness study to enhance the understanding of long-term severe events and clinical continuous outcomes of Fabrazyme among 5 subgroups identified by modified Arends criteria, estimate the disease progression after Fabrazyme treatment among Classic male patients with sustained anti-agalsidase beta immunoglobulin G (IgG) antibodies (ADA) and compare the long-term effectiveness of Fabrazyme between Classic patients with lower-dose regimen and those with standard-dose regimen." Request for Supplementary Information adopted on 28.01.2021.	
Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/II/0070/G Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, "- C.I.4 (Type II): Update of section 4.5 of the SmPC to include data on the drug-drug interaction between Genvoya and the thienopyridine anti-platelet drugs clopidogrel and prasugrel, based on a MAH cumulative safety review. The Package Leaflet is updated accordingly. - C.I.4 (Type II): Update of section 4.5 of the SmPC to include data on the drug-drug interaction between Genvoya and medicinal products or oral supplements containing polyvalent cations, based on a MAH cumulative safety review. The Package Leaflet is updated accordingly. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to correct the amount of lactose stated in section 2 of the	Request for supplementary information adopted with a specific timetable.

SmPC and make minor editorial changes throughout the PI." Request for Supplementary Information adopted on 11.03.2021, 10.12.2020.	
PRAC Led **Hemlibra - emicizumab - EMEA/H/C/004406/II/0021** Roche Registration GmbH, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Submission of an updated RMP version 2.5 in order to add thromboembolic events without concomitant aPCC as an important potential risk in the safety specifications and to update the milestones for BO40853/SURVEY study following approval of the protocol v3 (via MEA PRO 002.2)." Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
Jardiance - empagliflozin - EMEA/H/C/002677/II/0057 Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.2 and 4.4 of the SmPC to lower the renal threshold for initiation and use of empagliflozin depending on eGFR, and of the section 5.1 wording about endpoints with reference to EMPA-REG OUTCOME study. The PL is updated accordingly."	
Jinarc - tolvaptan - EMEA/H/C/002788/II/0031 Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Armando Genazzani, "Update of sections 4.2 and 4.4 of the SmPC in order to include information on patients with CKD late stage 4 based on final results from study 156-12-211 listed as a category 3 study in the RMP; this is a Phase 3b, Multicenter, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease." Request for Supplementary Information adopted on 10.12.2020.	
Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0017 Bayer AG, Rapporteur: Kirstine Moll Harboe, "Submission of the final report from the pharmacokinetic study 19742 comparing the	

pharmacokinetic parameters of Jivi vs. Adynovi."	
Keytruda - pembrolizumab - EMEA/H/C/003820/II/0094 Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "Update of sections 4.4 and 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-361 listed as a PAES in the Annex II; this is a Phase III Randomised, Controlled Clinical Trial of Pembrolizumab with or without Platinum-based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma; Annex IID is updated accordingly." Request for Supplementary Information adopted on 10.12.2020.	
Keytruda - pembrolizumab - EMEA/H/C/003820/II/0100 Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "Update of section 5.1 of the SmPC in order to update efficacy data based on interim results from study KEYNOTE-054 listed as a PAES in the Annex II; this is a randomized, double-blind, placebo-controlled phase 3 study evaluating pembrolizumab in the adjuvant therapy of patients with resected high-risk melanoma." Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
Lynparza - olaparib - EMEA/H/C/003726/II/0044 AstraZeneca AB, Rapporteur: Alexandre Moreau, "Update of sections 4.8 and 5.1 of the SmPC in order to provide final PFS2 and updated interim OS data from the Phase III PAOLA-1 study; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to switch the order of the capsule and tablet formulations in Annex 1 of the QRD." Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
Lynparza - olaparib - EMEA/H/C/003726/II/0045 AstraZeneca AB, Rapporteur: Alexandre Moreau, "Submission of the final report from study/D0816C00012 (ORZORA) listed as PAES in the Annex II of the Product Information. This	

is an Open Label, Single Arm, Multi-centre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed somatic or germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. The Annex II is updated accordingly."	
NexoBrid - concentrate of proteolytic enzymes enriched in bromelain - EMEA/H/C/002246/II/0049, Orphan MediWound Germany GmbH, Rapporteur: Janet Koenig, "Update of sections 4.2, 4.4, 4.8, 4.9, 5.1 and 5.2 of the SmPC based on interim results from study MW2010-03-02 (DETECT) listed as an obligation in the Annex II; this is a multicenter, multinational, randomized, controlled, assessor blinded, three-arm study performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to Gel Vehicle and compared to Standard of Care. The submitted Clinical Study Report includes data of Acute Phase and 12M Follow Up Period. The MAH also took the opportunity to submit integrated pooled analyses of efficacy and safety data obtained from phase 2 and phase 3 clinical studies to provide a comprehensive assessment of the safety and efficacy of NexoBrid. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 15.10.2020.	
Ocrevus - ocrelizumab - EMEA/H/C/004043/II/0023 Roche Registration GmbH, Rapporteur: Kirstine Moll Harboe, "Update of the SmPC section 5.1 with the newly available post-hoc analysis results related to the time-to-wheelchair data performed on clinical study WA25046 (ORATORIO) in the PPMS population." Opinion adopted on 04.03.2021. Request for Supplementary Information adopted on 28.01.2021.	Positive Opinion adopted by consensus on 04.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
POTELIGEO - mogamulizumab - EMEA/H/C/004232/II/0010/G, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Paula Boudewina van Hennik, "Update section 4.8 of the SmPC with the submission of data from	

study 0761-010 for ADA based on the revised assay as requested by the CHMP in order to review the revised data, and a reanalysis of the effect of ADA on safety, efficacy and mogamulizumab PK of subjects previously considered "inconclusive" now resulting in ADA positive. Update of section 4.6 to remove the statement on contraception requirements for male subjects/patients from the product information. The PL is updated accordingly. The MAH took the opportunity to update the PI in accordance with the latest QRD template v10.1."	
Rekovelle - follitropin delta - EMEA/H/C/003994/II/0023 Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race, "Update of section 5.1 of the SmPC in order to add information on dose equivalence factor to follitropin alfa based on clinical data from literature." Request for Supplementary Information adopted on 14.01.2021, 15.10.2020.	
Remicade - infliximab - EMEA/H/C/000240/II/0227 Janssen Biologics B.V., Rapporteur: Kristina Dunder, "Update of the breast-feeding information in section 4.6 of the SmPC to reflect the latest findings from literature regarding excretion of infliximab in human milk and the lack of impact on the development of breastfed infants. The local representative section in the package leaflet has also been updated."	
Remsima - infliximab - EMEA/H/C/002576/II/0095 Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, "Addition of a new posology for the rheumatoid arthritis indication that does not include IV induction doses." Request for Supplementary Information adopted on 10.12.2020.	See 9.1
Tecentriq - atezolizumab - EMEA/H/C/004143/II/0030 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update of section 4.8 of the SmPC to reflect the outcome of anti-drug antibody (ADA) analyses conducted across studies POPLAR, OAK, IMpower 150, IMpower 130, IMPower 131, IMpower 132, IMvigor 211, IMmotion 151,	

IMpower 133 and IMpassion 130, further to the CHMP recommendation." Request for Supplementary Information adopted on 14.01.2021, 08.10.2020, 23.04.2020, 05.12.2019.	
Thalidomide Celgene - thalidomide - EMEA/H/C/000823/II/0066 Celgene Europe BV, Rapporteur: Alexandre Moreau, "Update of section 4.8 to include PML. This change is being introduced following the approval of version 11 of the Company Core Data Sheet (CCDS) for thalidomide. The PIL is updated accordingly." Request for Supplementary Information adopted on 14.01.2021.	
Tygacil - tigecycline - EMEA/H/C/000644/II/0116 Pfizer Europe MA EEIG, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.6 and 5.3 of the SmPC to include the conclusions from preclinical studies conducted with tigecycline in rats, which do not indicate harmful effects with respect to fertility or reproductive performance. In addition, the MAH is taking the opportunity to update the SmPC and Package Leaflet to rectify the pharmaceutical form mentioned in the excipient information from "suspension" to "solution"." Opinion adopted on 18.03.2021.	Positive Opinion adopted by consensus on 18.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Tysabri - natalizumab - EMEA/H/C/000603/II/0123 Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, "C.I.4. Update of section 4.2 of the SmPC of Tysabri 300mg IV in order to modify administration instructions based on a review of clinical study database and global safety database reports. The Package Leaflet (section 2) is updated accordingly."	
Vaborem - meropenem / vaborbactam - EMEA/H/C/004669/II/0010/G Menarini International Operations Luxembourg S.A., Rapporteur: Filip Josephson, "A grouped application including 8 type II variations (C.I.4) and 1 type II variation (C.I.13): Update of section 4.5 of the SmPC based on the results of a series of non-clinical drug-drug interaction studies undertaken with vaborbactam or meropenem. The Package Leaflet has been updated accordingly. In	Request for supplementary information adopted with a specific timetable.

addition, the MAH has submitted non-clinical data on the phototoxicity potential of meropenem from a 3T3 neutral red uptake phototoxicity test." Request for Supplementary Information adopted on 11.03.2021.	
Venclyxto - venetoclax - EMEA/H/C/004106/II/0031 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, "to update venetoclax SmPC wording regarding Tumour lysis syndrome (TLS) prophylaxis and management following an update to the Company Core Data Sheet (CCDS) as result of a medical safety assessment conducted on TLS post-marketing reports. The proposed changes to the SmPC include section 4.2 and 4.4: • Section 4.2: A more prescriptive table which replaces the text around the risk assessment, prophylaxis and monitoring measures based on the level of tumour burden. In addition, the text on the recommended dose modifications for toxicities is replaced by a table format for clarity. • Section 4.4: the text is revised to emphasise the fact that TLS occur in all patients and requires adequate risk assessment that considers comorbidities, particularly renal impairment, and other risk factors such as splenomegaly." Request for Supplementary Information adopted on 25.02.2021, 12.11.2020.	
Vyndaqel - tafamidis - EMEA/H/C/002294/II/0067, Orphan Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "C.I.4 Update of section 4.5 of the SmPC in order to add drug-drug interaction information with Rosuvastatin, a breast cancer resistant protein (BCRP) and organic anion transporter 3 (OAT3) substrate, based on final results from study B3461075. This is a Phase 1 interventional clinical drug-drug interaction study to estimate the effect of a multiple oral administration of Tafamidis on Rosuvastatin in pharmacokinetics (PK) in healthy participants." Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
Wakix - pitolisant - EMEA/H/C/002616/II/0023/G, Orphan	Request for supplementary information adopted with a specific timetable.

Bioprojet Pharma, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Kirsti Villikka, "Update of the product information based on new clinical data from the open-label, long-term treatment of EDS (with or without cataplexy) in narcolepsy P09-10 HARMONY III study, and the randomised, double-blind, placebo-controlled, drug abuse potential study (P16-02). The proposed update also includes results of a post-approval network meta-analysis which compares efficacy and safety of multiple treatments, multi-arm studies, and multi-criteria treatment decisions." Request for Supplementary Information adopted on 11.03.2021, 14.01.2021, 03.09.2020.	
Xerava - eravacycline - EMEA/H/C/004237/II/0012 Tetraphase Pharmaceuticals Ireland Limited, Rapporteur: Filip Josephson, "Update of sections 5.3 and 6.6 of the SmPC in order to update the results of the Environmental Risk Assessment studies following their completion." Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
Xtandi - enzalutamide - EMEA/H/C/002639/II/0050 Astellas Pharma Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.8 of the SmPC in order to add severe skin reactions to the list of adverse drug reactions (ADRs) with frequency not known based on a safety review; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor corrections in the SmPC." Opinion adopted on 04.03.2021. Request for Supplementary Information adopted on 26.11.2020.	Positive Opinion adopted by consensus on 04.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1969 **Aprovel-EMEA/H/C/000141/WS1969/0183** **CoAprovel-EMEA/H/C/000222/WS1969/0202** **Karvea-EMEA/H/C/000142/WS1969/0185** **Karvezide-EMEA/H/C/000221/WS1969/0202** sanofi-aventis groupe, Duplicate, Duplicate of Karvezide, Lead Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.8 of the SmPC	

in order to add anemia to the list of adverse drug reactions with frequency unknown based on a review of the available data including the MAH database and a literature review; the Package Leaflet is updated accordingly."	
WS1989 **Combivir-EMEA/H/C/000190/WS1989/0100** **Epivir-EMEA/H/C/000107/WS1989/0116** **Trizivir-EMEA/H/C/000338/WS1989/0121** ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race, "Update of section 4.9 of the SmPC to revise the overdose information." Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
WS1990 **Combivir-EMEA/H/C/000190/WS1990/0099** **Dovato-EMEA/H/C/004909/WS1990/0018** **Epivir-EMEA/H/C/000107/WS1990/0115** **Kivexa-EMEA/H/C/000581/WS1990/0088** **Triumeq-EMEA/H/C/002754/WS1990/0087** **Trizivir-EMEA/H/C/000338/WS1990/0120** ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race, "Update of sections 4.2 and 5.2 of the SmPC to revise the information about use of the products in patients with renal impairment."	
WS1995 **Afinitor-EMEA/H/C/001038/WS1995/0069** **Votubia-EMEA/H/C/002311/WS1995/0068** Novartis Europharm Limited, Lead Rapporteur: Janet Koenig, "Update of the Afinitor and Votubia SmPCs to include radiation recall syndrome as an adverse drug reaction observed in the post-marketing phase with unknown frequency (section 4.8) and a cautionary text regarding radiation therapy complications in 'Special warnings and precautions for use' (section 4.4). Corresponding changes are also made to the package leaflets. Taking the opportunity, the MAH also proposes some editorial changes to harmonise the information in Afinitor and Votubia labels in SmPC (Section 4.7) 'Effects on ability to drive and use machines' and Package leaflet '.....(Afinitor/Votubia) with food and drink.'	

Afinitor label is further updated in compliance with the QRD template version 10.1, while Votubia label was already updated within the procedure II/061.”	

B.5.3. CHMP-PRAC assessed procedures

BLINCYTO - blinatumomab - EMEA/H/C/003731/II/0039, Orphan Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Eva Jirsová, “C.I.13 Submission of the final report from study 20180138 classified as category 3 PASS in RMP. This is an observational clinical study to update the OS Kaplan-Meier probability estimates and the plot last reported in the randomized Phase 3 blinatumomab 00103311 study.” Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
EXJADE - deferasirox - EMEA/H/C/000670/II/0075 Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, “The PI has been updated to remove discrepancies between SmPC and PL in sections `Pregnancy and breast-feeding' and section `Other medicines and EXJADE'. Furthermore, the Exjade SmPC and PL have been updated according to the Guidelines on excipients in the labelling and package leaflet of medicinal products for human use, Rev. 2. The MAH took also the opportunity to align the PI with the latest QRD template v. 10.1 and update the details of local representatives in EE, LV and NL. The Annex IID has been updated to reflect the new milestone for study CICL670E2422. In addition, the EU RMP version 19.0 for Exjade has been revised to introduce following changes: · Removal of the important identified risk, “Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, Toxic epidermal necrolysis and Drug reaction with eosinophilia and systemic symptoms)” · Change to the milestone for study CICL670E2422 (category 1) and change to RMP commitment deliverable and milestone for study	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

CICL670F2202 (category 3) · Removal of the study CICL670F2429 (category 1) due to fulfilment of the corresponding Post-Authorisation Measure · Removal of the expedited reporting requirement for the serious Adverse Drug Reactions (ADRs), 'Increase in hepatic enzymes >10 x upper limit of normal (ULN)', 'Serious rise in creatinine', 'results of renal biopsies', 'cataracts', 'hearing loss', gallstones' as agreed during PRAC PSUR Assessment (Procedure no.: EMEA/H/C/PSUSA/00000939/201910).” Opinion adopted on 11.03.2021. Request for Supplementary Information adopted on 14.01.2021.	
Galafold - migalastat - EMEA/H/C/004059/II/0030, Orphan Amicus Therapeutics Europe Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ulla Wändel Liminga, “Update of section 5.1 of the SmPC based on final results from study AT1001-042 listed as category 3 in the RMP. Study AT1001-042-is an open-label, non-comparative, long-term extension study to evaluate long-term safety and efficacy of migalastat l monotherapy in subjects with Fabry disease. The updated RMP version 5.1 has also been submitted.” Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Kalydeco - ivacaftor - EMEA/H/C/002494/II/0094, Orphan Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, “Submission of the final report from study VX15-770-122 listed as a category 3 study in the RMP. This is a study in US Cystic Fibrosis Patients with the R117H-CFTR mutation to confirm the long-term safety and effectiveness of Kalydeco, including patients <18 Years of age, combining data captured in the Cystic Fibrosis Foundation Patient Registry from an interventional cohort and a non-interventional cohort. In addition, the MAH took the opportunity to propose a change of due date for study 126, listed as a category 3 in the RMP. The RMP version 10.1 is acceptable.” Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Kisplyx - lenvatinib - EMEA/H/C/004224/II/0041 Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: David Olsen, "Update of section 4.5 of the SmPC in order to update the drug-drug interaction with everolimus based on data from study 221, a single-arm, multicenter, Phase 2 trial to evaluate the safety and efficacy of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic nccRCC who have not received any chemotherapy for advanced disease. (MEA 008.1). The RMP version 12.1 is submitted." Request for Supplementary Information adopted on 11.02.2021.	
Maviret - glecaprevir / pibrentasvir - EMEA/H/C/004430/II/0039 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Ana Sofia Diniz Martins, "Update of section 5.1 of the SmPC based on results from study M13-576; a non-drug interventional follow-up study to assess resistance and durability of response to AbbVie direct-acting antiviral agent (DAA) therapy (ABT-493 and/or ABT-530) in subjects who participated in Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C Virus (HCV) infection. The study is included as a category 3 study in the RMP, and an updated RMP version 6.0 has also been submitted." Request for Supplementary Information adopted on 11.02.2021.	
Mekinist - trametinib - EMEA/H/C/002643/II/0043 Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: David Olsen, "Submission of the final report from study 201711 listed as a category 3 study in the RMP. This is a study to identify and characterise the risk of cardiomyopathy and subsequent sequelae, including safety evaluations of patient populations at highest risk for developing these toxicities. The RMP version 17.0 has also been submitted." Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Natpar - parathyroid hormone - EMEA/H/C/003861/II/0026, Orphan	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP

Shire Pharmaceuticals Ireland Limited, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Rhea Fitzgerald, "Submission of the final results of study PAR-C10-008; a long-term open-label study investigating the safety and tolerability of a rhPTH[1-84] for the treatment of adults with hypoparathyroidism – a clinical extension study (RACE). Update of SmPC section 5.1 to reflect 72 month data from the study. Update of the RMP (version 3.0) with the completed study results, to remove this study as an additional pharmacovigilance activity and to align with the GVP module V Rev 2." Opinion adopted on 11.03.2021. Request for Supplementary Information adopted on 26.11.2020.	Members were in agreement with the CHMP recommendation.
NINLARO - ixazomib - EMEA/H/C/003844/II/0026, Orphan Takeda Pharma A/S, Rapporteur: Armando Genazzani, PRAC Rapporteur: Annika Folin, "Update of Annex II of the Product Information and the Risk Management Plan v. 5.1 following the completion of study C16014 comparing ixazomib plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with newly diagnosed multiple myeloma not eligible for stem cell transplantation (SCT) in fulfilment of SOB 003. A minor editorial change is proposed to section 4.2 Posology and Method of administration, for consistency with other sections of the SmPC. In addition, an update is proposed to the local representatives information in the Package Leaflet." Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
OFEV - nintedanib - EMEA/H/C/003821/II/0040 Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4. and 4.8 of the SmPC in order to add nephrotic range proteinuria as a new adverse drug reaction; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor corrections and editorial changes (correction of frequency category for renal failure in section 4.8 of the SmPC, correction of a typo of non-safety relevant information in section 5.1. of the SmPC and correction of typos	Request for supplementary information adopted with a specific timetable.

in Annex II) in the EN PI." Request for Supplementary Information adopted on 11.03.2021.	
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0009/G Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "C.I.4, C.I.3, C.I.6 (non-EoI) Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on results from study CSR 19-514 (PK Comparability) and CSR 16-508 (Japanese Ethnicity Study) listed as a specific obligation in the Annex II. Annex II was proposed to be updated accordingly. The RMP version 2.1 has also been submitted." Request for Supplementary Information adopted on 10.12.2020, 30.04.2020.	
OPDIVO - nivolumab - EMEA/H/C/003985/II/0098 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 5.1 of the SmPC in order to update overall survival information based on the final OS data for study CA209238, listed as an obligation in the Annex II and in the RMP; study CA 209238 is a Phase 3, randomised double-blind study of OPDIVO versus Yervoy in patients who have undergone complete resection of Stage IIIb/c or Stage IV melanoma; the MAH took also the occasion to update section 4.8 of the SmPC to pull the safety data sets of nivolumab as monotherapy across advanced metastatic and adjuvant settings. The Package Leaflet is updated accordingly. The RMP version 17.2 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial and formatting revisions in the PI." Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Qtern - saxagliptin / dapagliflozin - EMEA/H/C/004057/II/0031 AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ilaria Baldelli, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to reflect new data based on final results from study D1693C00001 (DECLARE). This is a multi-centre, randomised, double-blind, placebo-controlled study to evaluate the effect	

of dapagliflozin on cardiovascular (CV) and renal outcomes in patients with T2DM with or without established CV disease. The labelling and Package Leaflet (PL) are updated accordingly. The Risk Management Plan (RMP) v5.1 has also been updated. The MAH took the opportunity to make additional editorial changes to the PI." Request for Supplementary Information adopted on 28.01.2021.	
Repatha - evolocumab - EMEA/H/C/003766/II/0048 Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kimmo Jaakkola, "C.I.13: Submission of the final report from study 20130286 listed as a category 3 study in the RMP. This is a double blind, randomized, placebo controlled, multicenter study to evaluate safety, tolerability, and efficacy on LDL-C of evolocumab in HIV positive patients with hyperlipidemia and mixed dyslipidemia. The RMP version 6.0 has also been submitted." Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Rinvoq - upadacitinib - EMEA/H/C/004760/II/0009 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "C.I.4 - Update of sections 4.4 and 5.1 of the SmPC in order to amend the existing warning on vaccination based on the final results from vaccination substudy (within study M13-538) listed as a category 3 study in the RMP; this is an open-label extension to assess the impact of upadacitinib treatment with a stable background of methotrexate on immunological responses following administration of a pneumococcal vaccine in rheumatoid arthritis patients. The RMP version 5.0 has also been submitted."	
Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0037 GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, PRAC Rapporteur: Sonja Hrabcik, "To update section 4.4 of the SmPC following the final results from study ZOSTER-064, listed as a category 3 study in the RMP; this is an observational study to assess frailty	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

and other prognostic factors for development of herpes zoster in adult subjects who participated in studies ZOSTER-006 and ZOSTER-022 and the HZ efficacy, immunogenicity and safety of Shingrix by frailty status, in order to fulfil the post-authorisation measure MEA/FSR 012. The updated RMP version 4.1 has also been submitted. The MAH takes the opportunity to implement some editorial changes in sections 4.4 and 5.1 and correction of the abbreviation CHO cells from Chinese Hamster Ovarian cells to Chinese Hamster Ovary cells in the Annex A." Opinion adopted on 11.03.2021. Request for Supplementary Information adopted on 26.11.2020.	
Sivextro - tedizolid phosphate - EMEA/H/C/002846/II/0037 Merck Sharp & Dohme B.V., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon, "Update of section 5.1 of the SmPC in order to update the description of the potential risk of emergence of drug resistance with tedizolid phosphate, based on final results from study Surveillance of Tedizolid Activity and Resistance (STAR) listed as a category 3 study in the RMP; this is a surveillance study established in January 2014 to monitor tedizolid susceptibility activity and emergence of resistance across the US, 11 European Union countries, Russia and Turkey. The RMP version 6.2 has also been submitted." Opinion adopted on 11.03.2021. Request for Supplementary Information adopted on 26.11.2020, 03.09.2020.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Tafinlar - dabrafenib - EMEA/H/C/002604/II/0049 Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, "Submission of the final report from study 201710 listed as a category 3 study in the RMP. This is a study to perform evaluation of secondary malignancies in patients treated with dabrafenib in randomized, controlled trials. RMP version 10.1 had also been submitted." Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Tasigna - nilotinib - EMEA/H/C/000798/II/0107 Novartis Europharm Limited, Rapporteur: Sinan	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

B. Sarac, PRAC Rapporteur: Anette Kirstine Stark, "Submission of the 5 year data including data on late relapses from the ongoing studies ENESTfreedom (CAMN107I2201): A Phase II, single-arm, open-label, multicenter nilotinib TFR study in patients with BCR-ABL1 positive CML-CP, who had achieved durable minimal residual disease (MRD) status on first-line nilotinib treatment and ENESTop (CAMN107A2408): A Phase II, single-arm, open-label, multicenter study, evaluating TFR in patients with BCR-ABL1-positive CML-CP who achieved a sustained molecular response of MR4.5 on nilotinib treatment after switching from imatinib to nilotinib. Consequently, the RMP (version) 23 is being updated to remove the additional pharmacovigilance activity 'collection and submission of data on late relapses from the ongoing studies ENESTfreedom (CAMN107I2201) and ENESTop (CAMN107A2408)' and the safety concern 'risk of resistance (in TFR)'." Opinion adopted on 11.03.2021. Request for Supplementary Information adopted on 14.01.2021.	recommendation.
Xeljanz - tofacitinib - EMEA/H/C/004214/II/0027 Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of sections 4.1, 4.2, 4.4 , 4.8, 5.1 and 5.2 of Xeljanz 11 mg prolonged-release tablets SmPC in order to include the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug therapy; as an alternative to the immediate release film-coated tablets; Section 4.2 of Xeljanz film-coated tablets is also updated to include switching with the prolonged-release tablet in the treatment of PsA. The Package Leaflet is updated accordingly. The RMP version 13.1 has also been submitted." Request for Supplementary Information adopted on 10.12.2020.	See 9.1
Zercepac - trastuzumab - EMEA/H/C/005209/II/0008 Accord Healthcare S.L.U., Rapporteur: Sol Ruiz, PRAC Rapporteur: Brigitte Keller-Stanislawski	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 11.03.2021.	
Zykadia - ceritinib - EMEA/H/C/003819/II/0034 Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to reflect the results of study CLDK378A2112 as recommended by the CHMP. The study assesses the steady-state PK of 450 mg or 600 mg ceritinib taken daily with a low-fat meal as compared with that of 750 mg ceritinib taken daily in the fasted state in patients with metastatic ALK-positive NSCLC. The Package Leaflet is updated accordingly. The RMP version 16 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1. Other editorial changes include the addition of the Sodium content in the SmPCs and PLs and the removal of the black triangle." Opinion adopted on 11.03.2021. Request for Supplementary Information adopted on 26.11.2020.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.4. PRAC assessed procedures

PRAC Led **Aclasta - zoledronic acid - EMEA/H/C/000595/II/0076** Novartis Europharm Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Provision of an updated RMP version 13.2. Proposed changes: 1. Alignment with requirements of GVP Module V Rev.2 with consequential removal/ reclassification of a number of important potential risks; 2. Consequential removal of educational material for renal risk (renal dysfunction and use in patients with severe renal impairment); 3. Removal of 'post-dose symptoms' from the list of important identified risks (following the assessment of LEG 037 & variation II/74/G); 4. Update of the targeted questionnaire related to the ONJ risk (following the assessment of LEG 035); 5. Inclusion of the completed 5-year registry	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

study ZOL446H2422 (following the assessment of variation II-69 & MEA 017.1). The additional risk minimisation measures in the Annex II of the product information are updated accordingly." Opinion adopted on 11.03.2021. Request for Supplementary Information adopted on 11.02.2021, 01.10.2020.	
PRAC Led **Brineura - cerliponase alfa - EMEA/H/C/004065/II/0027, Orphan** BioMarin International Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "An update to the RMP, to change the final date for the completion of the Post-authorisation efficacy study 190-203 (final CSR)" Opinion adopted on 11.03.2021. Request for Supplementary Information adopted on 26.11.2020.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Conbriza - bazedoxifene - EMEA/H/C/000913/II/0052** Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final clinical study report (CSR) for the Conbriza Non-Interventional EU Post Authorisation Safety Study (EU PASS) - Protocol B1781044. This final CSR relates to the Post Approval Measure EMEA/H/C/000913/MEA 012.12." Request for Supplementary Information adopted on 11.03.2021, 03.09.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Eylea - aflibercept - EMEA/H/C/002392/II/0068** Bayer AG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "The submission contains the study report of the PASS study Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Europe: A Follow-up Physician survey. The study was requested as a category 3 study. RMP has been updated accordingly (version 27.1)." Request for Supplementary Information adopted on 14.01.2021.	
PRAC Led	Positive Opinion adopted by consensus on

Latuda - lurasidone - EMEA/H/C/002713/II/0033 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A., Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Filip Josephson, "Submission of a non-interventional PASS final study report for the Evaluation of the safety profile of lurasidone: a post-authorisation safety study using United States administrative claims databases. The primary objective was to compare the incidence of important identified risks and important potential risks in patients treated with lurasidone to patients treated with other second-generation oral atypical antipsychotics (OAAs)." Opinion adopted on 11.03.2021.	11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0062** Teva B.V., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka, PRAC-CHMP liaison: Outi Mäki-Ikola, "Submission of the final report from study XM22-ONC-5002 listed as a category 3 study in the RMP. This is a drug utilisation study on the prescribing patterns of lipegfilgrastim in the EU. The RMP version 13.0 has also been submitted." Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Lopinavir/Ritonavir Mylan - lopinavir / ritonavir - EMEA/H/C/004025/II/0016** Mylan S.A.S, Generic, Generic of Kaletra, Rapporteur: John Joseph Borg, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Jean-Michel Race, "Submission of an updated RMP v. 4.0 in order to implement the RMP template in accordance with GVP Module V rev. 2 and to align the safety concerns with the reference product" Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0079** Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from study	Request for supplementary information adopted with a specific timetable.

ALGMYC07390, Prevalence of immunology testing in patients treated with alglucosidase alfa with significant hypersensitivity/anaphylactic reactions (MEA 053 resulting from variation EMEA/H/C/000636/II/0052) to test the effectiveness of the approved Safety Information Packet (SIP)." Request for Supplementary Information adopted on 11.03.2021, 26.11.2020, 09.07.2020, 12.03.2020.	
PRAC Led **Neulasta - pegfilgrastim - EMEA/H/C/000420/II/0114** Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Update of section 6.6 of the SmPC in order to add a new warning that the medicine should be allowed to reach room temperature before use, based on cumulative reviews of post-marketing reports of medication errors with the on-body injector and in response to the PAM EMEA/H/C/000420/MEA/060.3. The MAH also took the opportunity to introduce an editorial change in section 4.4 of the SmPC." Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Piqray - alpelisib - EMEA/H/C/004804/II/0001** Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 2.0 in order to replace the category 3 studies CBYL719C2402 and CBYL719A0IC02 with a new non interventional safety study (CBYL719C2404). Additionally, a separated Health Care Professional Survey (CBYL719A0IC02) is proposed as part of the pharmacovigilance plan." Opinion adopted on 11.03.2021. Request for Supplementary Information adopted on 26.11.2020.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Retacrit - epoetin zeta - EMEA/H/C/000872/II/0100** Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-	Request for supplementary information adopted with a specific timetable.

CHMP liaison: Martina Weise, "Submission of the final study report of a joint post-authorisation safety cohort study of Retacrit/Silapo (epoetin zeta) administered subcutaneously for the treatment of renal anemia (PASCO II) listed as a category 3 study in the RMP. The primary objective of the observational study was to estimate the incidence of pure red cell aplasia (PRCA), neutralising antibodies, lack of efficacy and thromboembolic events under treatment with Retacrit/Silapo (epoetin zeta). The RMP version 16 has also been submitted." Request for Supplementary Information adopted on 11.03.2021.	
PRAC Led **Silapo - epoetin zeta - EMEA/H/C/000760/II/0062** STADA Arzneimittel AG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final study report of a joint post-authorisation safety cohort study of Retacrit/Silapo (epoetin zeta) administered subcutaneously for the treatment of renal anemia (PASCO II) listed as a category 3 study in the RMP. The primary objective of the observational study was to estimate the incidence of pure red cell aplasia (PRCA), neutralising antibodies, lack of efficacy and thromboembolic events under treatment with Retacrit/Silapo (epoetin zeta). The RMP version 12 has also been submitted." Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Vyxeos liposomal - daunorubicin / cytarabine - EMEA/H/C/004282/II/0017, Orphan** Jazz Pharmaceuticals Ireland Limited, Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, "Submission of a final CSR for post-marketing observational study of Vyxeos liposomal to assess the incidence of infusion-related reactions in adult patients. The primary objective of this study is to assess the nature, incidence, and severity of infusion-related reactions during and for up to one day following the last infusion of a five-day induction course in patients treated with the product. The	Request for supplementary information adopted with a specific timetable.

secondary objective is to assess this information during and for up to one day following the last infusion of a five-day induction course in patients treated with Vyxeos." Request for Supplementary Information adopted on 11.03.2021.	
PRAC Led **WS2011** **AZILECT-EMEA/H/C/000574/WS2011/0087** **Rasagiline ratiopharm-EMEA/H/C/003957/WS2011/0019** Teva B.V., Lead Rapporteur: Bruno Sepodes, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "C.I.11.b for RMP: Submission of an updated RMP version 3.0 following the completion of TV1030-CNS-50024 PASS (cat 3) study investigating the risk of melanoma among Parkinson's Disease Patients (final study results already assessed in EMEA/H/C/WS/1749). The Applicant took the opportunity to submit a minor update to targeted follow-up questionnaire for the important potential risk of malignant melanoma and to revise the list of safety concerns and RMP format in line with GVP Module V revision 2.0.1 RMP template requirements." Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.

B.5.5. CHMP-CAT assessed procedures

Spherox - spheroids of human autologous matrix-associated chondrocytes - EMEA/H/C/002736/II/0022, ATMP CO.DON AG, Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder, "Update of section 5.1 of the SmPC with the final results of study cod 16 HS 13, a 60-month follow up data assessing long-term efficacy and safety of Spherox. Annex II has also been updated to reflect the completion of the study."	
Yescarta - axicabtagene ciloleucel - EMEA/H/C/004480/II/0030, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus	

Request for Supplementary Information adopted on 22.01.2021.	
Yescarta - axicabtagene ciloleucel - EMEA/H/C/004480/II/0031, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Request for Supplementary Information adopted on 22.01.2021.	

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS1962/G **Keppra-EMEA/H/C/000277/WS1962/0191/G** UCB Pharma S.A., Lead Rapporteur: Karin Janssen van Doorn, Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1967/G **Incresync-EMEA/H/C/002178/WS1967/0037/G** **Vipdomet-EMEA/H/C/002654/WS1967/0032/G** **Vipidia-EMEA/H/C/002182/WS1967/0026/G** Takeda Pharma A/S, Lead Rapporteur: Johann Lodewijk Hillege, "C.I.z To bring the annexes in line with QRD version 10.1 and to updated the contact details of the local representatives in BE, DE, ES, FR, LU, LT, NL and PL. The MAH also brought the annexes of Incresync and Vipidia in line with the guidance on excipients for sodium. A.1 To change the address of the marketing authorisation holder, Takeda Pharma A/S, from Dybendal Alle 10, 2630 Taastrup, Denmark to Delta Park 45, 2665 Vallensbæk Strand Denmark."	
WS1980 **Axura-EMEA/H/C/000378/WS1980/0082** **Memantine Merz-EMEA/H/C/002711/WS1980/0018**	

Merz Pharmaceuticals GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro, "To align the wording regarding sorbitol, potassium and sodium in accordance to the standard wording listed in the Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' in the national product information." For the oral solution the excipient potassium is also being deleted in the SmPC section 2 Qualitative and quantitative composition and in the labelling. Also the wording for sorbitol for Axura (or Mementine Merz) 5 mg/pump actuation, is being updated in line with the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' In addition, the MAH is taking this opportunity to update the details of the local representative in Austria." Request for Supplementary Information adopted on 04.02.2021.	
WS1988 **Ambirix-EMEA/H/C/000426/WS1988/ 0112** **Twinrix Adult-EMEA/H/C/000112/WS1988/ 0147** **Twinrix Paediatric-EMEA/H/C/000129/ WS1988/0148** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1993/G **Suboxone-EMEA/H/C/000697/WS1993/0050/G** Indivior Europe Limited, Lead Rapporteur: Janet Koenig Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1994 **Ambirix-EMEA/H/C/000426/WS1994/ 0113** **Fendrix-EMEA/H/C/000550/WS1994/ 0074** **Infanrix hexa-EMEA/H/C/000296/ WS1994/0293** **Twinrix Adult-EMEA/H/C/000112/ WS1994/0148** **Twinrix Paediatric-EMEA/H/C/000129/**	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

WS1994/0149 GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 11.03.2021.	
WS1998/G **Abseamed-EMEA/H/C/000727/WS1998/0091/G** **Binocrit-EMEA/H/C/000725/WS1998/0090/G** **Epoetin alfa Hexal-EMEA/H/C/000726/WS1998/0090/G** Sandoz GmbH, Lead Rapporteur: Alexandre Moreau Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1999 **Nuwiq-EMEA/H/C/002813/WS1999/0040** **Vihuma-EMEA/H/C/004459/WS1999/0022** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 04.03.2021. Request for Supplementary Information adopted on 21.01.2021.	Positive Opinion adopted by consensus on 04.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2005/G **Hexacima-EMEA/H/C/002702/WS2005/0114/G** **Hexyon-EMEA/H/C/002796/WS2005/0118/G** Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus	
WS2007 **Atectura Breezhaler-EMEA/H/C/005067/WS2007/0003** **Bemrist Breezhaler-EMEA/H/C/005516/WS2007/0003** Novartis Europharm Limited, Lead Rapporteur: Peter Kiely Opinion adopted on 11.03.2021.	Positive Opinion adopted by consensus on 11.03.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2015 **Lyrica-EMEA/H/C/000546/WS2015/0111** **Pregabalin Pfizer-EMEA/H/C/003880/WS2015/0040** Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, "To update section 5.1 of the SmPC following completion of a paediatric study (A0081105) in line with the outcome of the Article 46 (EMEA/H/C/003880/P46/006.1 and	

EMEA/H/C/003880/P46/006) and Post-authorisation Measure (PAM) procedure (EMEA/H/C/000546/P46/053.1 and EMEA/H/C/003880/P46/006.1). In addition the MAH brought that annexes in line with QRD version 10.1 and a reference to the reporting of side effects that had been duplicated was removed.”	
WS2019 **Copalia-EMEA/H/C/000774/WS2019/0116** **Copalia HCT-EMEA/H/C/001159/WS2019/0091** **Dafiro-EMEA/H/C/000776/WS2019/0120** **Dafiro HCT-EMEA/H/C/001160/WS2019/0093** **Exforge-EMEA/H/C/000716/WS2019/0115** **Exforge HCT-EMEA/H/C/001068/WS2019/0090** Novartis Europharm Limited, Lead Rapporteur: Kirstine Moll Harboe Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
WS2021/G **Exelon-EMEA/H/C/000169/WS2021/0133/G** **Prometax-EMEA/H/C/000255/WS2021/0133/G** Novartis Europharm Limited, Lead Rapporteur: Alexandre Moreau	
WS2022/G **Copalia-EMEA/H/C/000774/WS2022/0115/G** **Copalia HCT-EMEA/H/C/001159/WS2022/0089/G** **Dafiro-EMEA/H/C/000776/WS2022/0119/G** **Dafiro HCT-EMEA/H/C/001160/WS2022/0091/G** **Exforge-EMEA/H/C/000716/WS2022/0114/G** **Exforge HCT-EMEA/H/C/001068/WS2022/0088/G** Novartis Europharm Limited, Lead Rapporteur: Kirstine Moll Harboe, Request for Supplementary Information adopted on 11.03.2021.	Request for supplementary information adopted with a specific timetable.
WS2023/G **Copalia-EMEA/H/C/000774/WS2023/**	

0117/G
Dafiro-EMEA/H/C/000776/WS2023/
0121/G
Exforge-EMEA/H/C/000716/WS2023/
0116/G
Novartis Europharm Limited, Lead Rapporteur: Kirstine Moll Harboe,

WS2029
Nuwiq-EMEA/H/C/002813/WS2029/0041
Vihuma-EMEA/H/C/004459/WS2029/
0023
Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus

Mosquirix-EMEA/H/W/002300/WS1961/
0052
Shingrix-EMEA/H/C/004336/WS1961/
0040
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Jan Mueller-Berghaus
Request for Supplementary Information adopted on 11.02.2021.

B.5.9. Information on withdrawn type II variation / WS procedure

Respreeza - human alpha1-proteinase inhibitor - EMEA/H/C/002739/II/0051 CSL Behring GmbH, Rapporteur: Kristina Dunder Withdrawal request submitted on 04.03.2021.	The MAH withdrew the procedure on 04.03.2021.

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

gefapixant - EMEA/H/C/005884
treatment of refractory or unexplained chronic cough

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

ranibizumab - EMEA/H/C/005545
treatment of neovascular age-related macular

degeneration (AMD)
List of Questions adopted on 28.01.2021.

icatibant - EMEA/H/C/005083
treatment of hereditary angioedema
List of Questions adopted on 10.12.2020.

elivaldogene autotemcel - EMEA/H/C/003690, Orphan, ATMP
bluebird bio (Netherlands) B.V, treatment of ABCD1 genetic mutation and cerebral adrenoleukodystrophy
List of Questions adopted on 22.01.2021.

tafasitamab - EMEA/H/C/005436, Orphan
Morphosys AG, is indicated in combination with lenalidomide followed by monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT).
List of Questions adopted on 17.09.2020.

Volibris - ambrisentan - EMEA/H/C/000839/X/0061/G
GlaxoSmithKline (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Eva A. Segovia, "Extension application to introduce a new strength (2.5 mg film-coated tablet), grouped with an extension of indication to include paediatric use (8 to less than 18 years). Version 9.0 of the RMP has been submitted. Type IA category A.7"
List of Questions adopted on 17.09.2020.

B.6.4. Annual Re-assessments: timetables for adoption

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

AYVAKYT - avapritinib - EMEA/H/C/005208/R/0007, Orphan
Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0088/G, Orphan
Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik

BESPONSA - inotuzumab ozogamicin - EMEA/H/C/004119/II/0020/G, Orphan
Pfizer Europe MA EEIG, Rapporteur: Filip Josephson

COMIRNATY - covid-19 mrna vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0011/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0012
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson
Opinion adopted on 12.03.2021.

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0017/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0018/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

COVID-19 Vaccine Moderna - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0004/G
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus

COVID-19 Vaccine Moderna - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0007/G
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus

HBVAXPRO - hepatitis B vaccine (rDNA) - EMEA/H/C/000373/II/0071/G
MSD Vaccins, Rapporteur: Jan Mueller-Berghaus

IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0064
Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus

Luveris - lutropin alfa - EMEA/H/C/000292/II/0089
Merck Europe B.V., Rapporteur: Kirstine Moll Harboe

Ogivri - trastuzumab - EMEA/H/C/004916/II/0028
Mylan S.A.S, Rapporteur: Karin Janssen van Doorn

Pergoveris - follitropin alfa / lutropin alfa - EMEA/H/C/000714/II/0072
Merck Europe B.V., Rapporteur: Kirstine Moll Harboe

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and Haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0076/G
MCM Vaccine B.V., Rapporteur: Christophe Focke

WS2012/G
Infanrix hexa-EMEA/H/C/000296/ WS2012/0297/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2018/G
Ambirix-EMEA/H/C/000426/WS2018/ 0114/G
Twinrix Adult-EMEA/H/C/000112/ WS2018/0149/G
Twinrix Paediatric-EMEA/H/C/000129/ WS2018/0150/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Alecensa - alectinib - EMEA/H/C/004164/II/0034
Roche Registration GmbH, Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add haemolytic anaemia to the list of adverse drug reactions (ADRs) with frequency

common, based on a report of cumulative safety data (DSR1104210); the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2. Moreover, the MAH took the opportunity to introduce editorial changes in the Greek, Swedish, Dutch, Danish, Latvian, Croatian, Portuguese and Czech PI."

Brilique - ticagrelor - EMEA/H/C/001241/II/0050

AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, "Update of the SmPC in order to add central sleep apnoea including Cheyne-Stokes respiration as a new warning in section 4.4. and in the list of adverse drug reactions (ADRs) section 4.8 with frequency not known, following collection of post-marketing data; the Package Leaflet is updated accordingly."

Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0019

ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to add data on efficacy and safety in treatment experienced, virologically suppressed subjects switching to the Dovato fixed dose combination tablet, based on the week 96 data results from the Phase III study 204862 (TANGO)."

Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0020

ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of section 4.8 in order to add new safety information regarding hepatic safety and section 5.1 to include long-term efficacy and safety information, based on studies 204861 (GEMINI-1) and 205543 (GEMINI-2), listed as category 3 studies in the RMP. GEMINI-1 and GEMINI-2 were Phase III, randomised, double-blind, multicentre, parallel group, non-inferiority studies evaluating the efficacy, safety and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Dupixent - dupilumab - EMEA/H/C/004390/II/0044

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, "C.I.4 – Update of section 4.8 of the SmPC to include the long-term safety data of dupilumab in adult patients with moderate to severe AD, following interim results from the OLE study (R668-AD-1225) listed as category 3 study in the RMP."	
Erleada - apalutamide - EMEA/H/C/004452/II/0013 Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.6 and 5.3 of the SmPC in order to update information on pregnancy, and update non-clinical information following results of a developmental toxicity study in rats."	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0028 AstraZeneca AB, Rapporteur: Sinan B. Sarac, "Submission of the final analyses of the CASPIAN study for the Durvalumab (D) + Tremelimumab (T) + etoposide-platinum chemotherapy (EP) vs. EP treatment comparison as recommended by the CHMP in the context of procedure EMEA/H/C/004771/II/0014/G. In addition, the MAH submits the results from the China Cohort incorporated in the CASPIAN study. This is an interventional study investigating the efficacy and safety of D ± T in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)."	
Kineret - anakinra - EMEA/H/C/000363/II/0080/G Swedish Orphan Biovitrum AB (publ), Rapporteur: Kirstine Moll Harboe, "Update of section 4.4 of the SmPC in order to include new safety information about Macrophage activation syndrome (MAS) in the 'serious infections' subsection and to update the 'pulmonary events' and the 'malignancies' subsections with new safety information. Update of section 4.8 of the SmPC to amend the summary of safety profile, the 'serious infections', the 'neutropenia', 'allergic reactions', 'immunogenicity', 'paediatric population' and the 'injection site reactions' subsections with new safety information.	

Update of section 5.1 of the SmPC to update the clinical efficacy and safety information in Still's disease. The updates proposed are based on the results from study Sobi.ANAKIN-301 (evaluated in procedure no. EMA/H/C/000363/P46/031) and Sobi.ANAKIN-302 (evaluated in procedure no. EMEA/H/C/000363/II/0073). Sobi.ANAKIN-301 was a randomised, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of anakinra as compared to placebo in newly diagnosed Still's disease patients (including systemic juvenile idiopathic arthritis [SJIA] and adult-onset Still's disease [AOSD]). Sobi.ANAKIN-302 was a non-interventional, post-authorisation safety study to evaluate long-term safety of anakinra in patients with SJIA." In addition, the MAH took the opportunity to correct in section 4.8 of the SmPC the frequency of the adverse reaction 'skin and subcutaneous tissue disorder' from 'very common' to 'uncommon'."	
LEDAGA - chlormethine - EMEA/H/C/002826/II/0027, Orphan Helsinn Birex Pharmaceuticals Limited, Rapporteur: Sinan B. Sarac, "Update of section 4.2 of the SmPC in order to allow flexibility in the starting frequency of the treatment based on current clinical practice; the Package Leaflet is updated accordingly."	
Nerlynx - neratinib - EMEA/H/C/004030/II/0021 Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, "Update of sections 5.3 and 6.6 of the SmPC based on an updated environmental risk assessment including ERA studies"	
Phesgo - pertuzumab / trastuzumab - EMEA/H/C/005386/II/0002 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to support the safety of switching from intravenous to subcutaneous route of administration or vice versa, based on results from study MO40628; this is a Phase II, randomised, open-label, cross-over study to assess preference for intravenous or	

subcutaneous route of administration in patients with HER2-positive early breast cancer."

Sunosi - solriamfetol - EMEA/H/C/004893/II/0009

Jazz Pharmaceuticals Ireland Limited, Rapporteur: Janet Koenig, "Update of section 4.8 of the SmPC in order to add hypersensitivity reactions to the list of adverse drug reactions (ADRs) following confirmation of a post-marketing safety signal for hypersensitivity. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes and to bring the PI in line with the latest QRD template version 10.2."

Tecentriq - atezolizumab - EMEA/H/C/004143/II/0058

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "C.I.4
Update of section 5.1 of the SmPC in order to include the updated efficacy results from study YO40245 (IMbrave150) with a data cut-off of 31 August 2020 as recommended by the CHMP in the context of variation EMEA/H/C/004143/II/0039; IMbrave 150 is a Phase III, open-label, multicenter, randomized, two-arm pivotal study designed to evaluate the efficacy and safety of atezolizumab + bevacizumab versus sorafenib in patients with locally advanced or metastatic hepatocellular carcinoma who had not received prior systemic treatment.
In addition, the MAH took the opportunity to clarify in section 4.4 of the SmPC that the exclusion of patients with hepatitis B or hepatitis C infection only applies to non-HCC patients."

Tecentriq - atezolizumab - EMEA/H/C/004143/II/0059

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "C.I.13: Submission of the final report from study MO39196 (IMpassion131), a phase III, multicenter, randomized, placebo-controlled study of Tecentriq in combination with paclitaxel in 1L metastatic triple negative breast cancer as recommended by the CHMP during procedure EMEA/H/C/004143/X/0017"

Tecentriq - atezolizumab - EMEA/H/C/004143/II/0060

Roche Registration GmbH, Rapporteur: Sinan B.

Sarac, "C.I.4 Update of section 4.2 of the SmPC in order to harmonise the atezolizumab posology regimen of 840 mg every 2 weeks, 1200 mg every 3 weeks and 1680 mg every 4 weeks administered as an IV infusion across the currently authorised indications of NSCLC, ES-SCLC, TNBC and HCC, based on PK modelling and simulation data. As a consequence of the harmonised dose schedules, the MAH is applying for a combined SmPC and PL. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include minor editorial changes to the PI."	
Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/II/0091 ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4 and 4.5 of the SmPC to include information on administration of an additional dose of 50 mg dolutergravir when Triumeq is co-administered with strong enzyme inducing drugs, sections 4.4 and 4.5 to include information on co-administration of Triumeq and supplements or multivitamins containing calcium, iron or magnesium when taken with food and section 5.2 to include information on the elimination half-life of lamivudine. The Package Leaflet is updated accordingly. These changes follow the CHMP request to align the Product Information of Triumeq and Dovato, made at the time of recommending the initial marketing authorisation of Dovato. In addition, the MAH took the opportunity to update the details of the Northern Ireland local representative in line with the QRD template v. 10.2."	
TRIXEO AEROSPHERE - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide - EMEA/H/C/004983/II/0002 AstraZeneca AB, Rapporteur: Peter Kiely, "C.I.4. Update of section 5.1. of the SmPC in order to add information on the effects on all-cause mortality based on the supplement to the study PT010005 Clinical Study Reporton all cause-mortality and additional data analyses to address the concerns identified during the	

evaluation of the MAA."

Verzenios - abemaciclib - EMEA/H/C/004302/II/0016/G
Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to include OS interim results from MONARCH 3 study, a randomised, double blind, placebo controlled phase 3 study in women with HR positive, HER2 negative locally advanced or metastatic breast cancer who had not received prior systemic therapy in this disease setting. In addition, the MAH is updating the ATC code in the SmPC. The MAH is also taking the opportunity to update the list of local representatives in the Package Leaflet in line with the QRD template 10.2."

B.6.10. CHMP-PRAC assessed procedures

COVID-19 Vaccine AstraZeneca - COVID-19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0002
AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.8, 5.1, 6.3 and 6.6 of the SmPC in order to update the safety profile and to add the adverse drug reactions: abdominal pain and urticaria with frequency uncommon; and pain in extremity and influenza-line illness with frequency common in section 4.8; based on the primary analysis (7th December data cut-off (post data-base lock) from the pooled pivotal studies (COV001, COV002, COV003 and COV005) that supported the conditional marketing authorisation and are listed as a specific obligation in the Annex II. The update on section 5.1 is editorial. The update in sections 6.3 and 6.6 relates to a rewording of the information of the shelf-life for opened vials for clarity purposes. The Package Leaflet and Labelling are updated accordingly. The MAH is taking the opportunity to update the product information in relation to the "genetically modified organisms" information. The RMP version 2.1 has also been submitted."

Lamzede - velmanase alfa - EMEA/H/C/003922/II/0018, Orphan
Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jan

Neuhauser, "Type II C.I.4 Update of sections 4.4, 4,8 and 5.1 of the SmPC in order to amend an existing warning on immunogenicity, update the summary of the safety profile, add cyanosis to the list of adverse drug reactions (ADRs) with frequency 'common', add the information that the safety profile observed in children under age 6 is consistent with what was observed in previous studies, update the pharmacodynamic properties. These proposed SmPC updates are based on the final results of rhLAMAN-08 study, which is listed as an Annex II study in the RMP, and is a 24-month multi-center, open-label phase II trial investigating the safety and efficacy of repeated velmanase alfa (recombinant human alpha-mannosidase) treatment in paediatric patients <6 years if age with alpha-mannosidosis. The Package Leaflet is being update accordingly. The RMP v8.1 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with QRD template v10.1 and v10.2."	
Nplate - romiplostim - EMEA/H/C/000942/II/0079 Amgen Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "Update of section 4.8 of the SmPC to add Anaphylactic reaction to the list of adverse drug reactions (ADRs) with frequency to be determined in the evaluation of the variation. The package leaflet has been amended accordingly."	
Tasigna - nilotinib - EMEA/H/C/000798/II/0109 Novartis Europharm Limited, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark, "Update of SmPC sections 4.4, 4.8 and 5.1 based on the 5-year follow up data from the study CAMN107A2203 in paediatric patients. Annex II D has been updated to reflect the fulfilment of the obligation to conduct the post authorisation efficacy study (PAES). The Package leaflet is updated accordingly. In addition, Tasigna EU RMP version 24.0 has been updated to remove the corresponding additional pharmacovigilance activity and the missing information 'Long-term follow-up in pediatric patients'."	
Xeljanz - tofacitinib -	

EMEA/H/C/004214/II/0038
Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, "Submission of an updated RMP version 17.1 in order to incorporate the category 3 US-based drug utilisation study A3921348 into the category 3 protocol of the US-based active surveillance study A3921347."

B.6.11. PRAC assessed procedures

PRAC Led
Alecensa - alectinib -
EMEA/H/C/004164/II/0033
Roche Registration GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Jana Lukacisinova, PRAC-CHMP liaison: Ondřej Slanař, "Submission of an updated RMP version 3.1 in order to remove the safety concern of missing information - long term safety, based on a report of the cumulative safety data from the pivotal Phase III clinical trial ALEX (BO28984). In addition, the MAH has taken the opportunity to update the RMP to remove study BO40643 from the pharmacovigilance plan, following assessment in procedure EMEA/H/C/004164/II/0030."

PRAC Led
Benlysta - belimumab -
EMEA/H/C/002015/II/0092
GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of an updated RMP version 40 in order to add an alternative pregnancy exposure study (study 213928) as a category 3 study for the missing information on limited data in pregnant and lactating patients. The study is to evaluate pregnancy and infant outcomes for pregnancies in women with SLE exposed to belimumab. The RMP includes also completion date and effectiveness for the DHPC in relation to the important identified risk of psychiatric events including depression and suicidality."

PRAC Led
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) -
EMEA/H/C/005735/II/0016/G
BioNTech Manufacturing GmbH, Rapporteur:

Filip Josephson, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Group of two type II variations C.I.3.b consisting of:

- One update of the section 4.8 SmPC to add 2 new adverse drug reactions (ADRs) ("diarrhea", "vomiting") with frequencies and update the ADR "pain in extremity" in order to fulfil MEA 002.2
- One update of the section 4.8 SmPC to update the ADR "hypersensitivity reactions" in more detail (e.g. "rash, pruritus, urticaria, angioedema") with the relevant frequency categories in order to fulfil LEG 022.1
- The section 4 of the Package Leaflet is updated accordingly.
- In addition, the MAH took the opportunity to perform an editorial change in section 6.6, as well as correction of some typos."

PRAC Led

OCALIVA - obeticholic acid - EMEA/H/C/004093/II/0026, Orphan

Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 1.2 in order to update the format in accordance with template to EMA/164014/2018 Rev.2.0.1 and to add Specific Obligation clinical studies 747-302 and 747-401 to the pharmacovigilance plan. This change has been agreed by the CHMP in the outcome Ocaliva 2020 Annual Renewal (EMEA/H/C/004093/R/0023).
Other changes also include an update to the exposure data from clinical studies and addition of data on post-marketing experience up to the DLP (26 May 2020) and addition of some specific relevant SmPC wording in the risk minimisation measures"

PRAC Led

Zevalin - ibritumomab tiuxetan - EMEA/H/C/000547/II/0053

Ceft Biopharma s.r.o., Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Sinan B. Sarac, "Update of the RMP in line with the new GVP module"

PRAC Led

WS2013

Abseamed-EMEA/H/C/000727/WS2013/0092
Binocrit-EMEA/H/C/000725/WS2013/0091
Epoetin alfa Hexal-EMEA/H/C/000726/WS2013/0091

Sandoz GmbH, Lead Rapporteur: Alexandre Moreau, Lead PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Update of the RMP v.18 for Abseamed, Binocrit, Epoetin Alfa Hexal in line with the RMP of the originator product Eprex.
The following changes have been introduced:

· Wording of two potential risks was harmonised in line with the originator's RMP: The term "tumor growth potential" was replaced with "disease progression", and "premature death" was replaced with "survival impact".
· The clinical study data on these two topics were shortened, in line with the originator's RMP.
· Removal of TRIGONS study proposal (MEA18; HX575-502) as additional pharmacovigilance activity; in alignment with originator RMP, risks of disease progression and survival impact will be monitored by routine pharmacovigilance and continue to be reviewed in PSURs.
· Statistical output tables were integrated into Annex 7 following a PRAC request."

PRAC Led
WS2040/G
Aybintio-EMEA/H/C/005106/WS2040/0004/G
Onbevzi-EMEA/H/C/005640/WS2040/0001/G

Samsung Bioepis NL B.V., Lead Rapporteur: Andrea Laslop, Lead PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Sinan B. Sarac, "C.I.11.z - To provide an updated RMP, to remove the missing information of "Long term effects of bevacizumab when used in the paediatric population" to align the safety concerns to the reference product Avastin.
C.I.2.a - To update sections 4.4, 5.1 and 6.6 of the SmPC following assessment of the same change for the reference product Avastin (procedure EMEA/H/C/000582/IB/0118).
In addition, the marketing authorisation holder has taken the opportunity to add the Date of

first authorisation in section 9 of the SmPC and align the PI with the latest QRD template (v. 10.2) for Onbevzi.”

B.6.12. CHMP-CAT assessed procedures

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

PRAC Led **Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0044, ATMP** Amgen Europe B.V., Rapporteur: Olli Tenhunen, CHMP Coordinator: Johanna Lähteenvuo, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, “Submission of the final report from study 20180099 listed as a category 3 study in the RMP. This is a cross-sectional survey to evaluate physician knowledge of safety messages included in the physician education booklet (PEB) for Imlygic.”

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2024 **Infanrix hexa-EMEA/H/C/000296/WS2024/0296** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke
WS2030 **Biktarvy-EMEA/H/C/004449/WS2030/0037** **Descovy-EMEA/H/C/004094/WS2030/0053** **Genvoya-EMEA/H/C/004042/WS2030/0075** **Odefsey-EMEA/H/C/004156/WS2030/0050** Gilead Sciences Ireland UC, Lead Rapporteur: Bruno Sepodes, “To update section 4.4 of the SmPC and section 2 of the PL with information regarding nephrotoxicity, in alignment with the outcome of procedure EMEA/H/C/PSUSA/00010575/201911 already approved for Vemlidy. In addition, the marketing authorisation holder has taken the opportunity to introduce minor

editorial changes for Biktarvy and to align the PI of all four products to the latest QRD template (v. 10.2).”
WS2033 **Hexacima-EMEA/H/C/002702/WS2033/0116** **Hexyon-EMEA/H/C/002796/WS2033/0120** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus
WS2045/G **OFEV-EMEA/H/C/003821/WS2045/0043/G** **Vargatef-EMEA/H/C/002569/WS2045/0040/G** Boehringer Ingelheim International GmbH, Lead Rapporteur: Peter Kiely,
WS2047 **HyQvia-EMEA/H/C/002491/WS2047/0069** **Kiovig-EMEA/H/C/000628/WS2047/0108** Baxalta Innovations GmbH, Lead Rapporteur: Jan Mueller-Berghaus
WS2051/G **Entresto-EMEA/H/C/004062/WS2051/0037/G** **Neparvis-EMEA/H/C/004343/WS2051/0035/G** Novartis Europharm Limited, Lead Rapporteur: Johann Lodewijk Hillege

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended

F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 22-25 March 2021 CHMP plenary:

G.2.2. List of procedures starting in March 2021 for April 2021 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address